Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Breast Cancer

  Free Subscription

Articles published in BMC Cancer

Retrieve available abstracts of 739 articles:
HTML format

Single Articles

    July 2021
  1. VIALA M, Firmin N, Touraine C, Pouderoux S, et al
    Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer.
    BMC Cancer. 2021;21:815.
    PubMed     Abstract available

  2. LI S, Wu J, Huang O, He J, et al
    Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients.
    BMC Cancer. 2021;21:807.
    PubMed     Abstract available

  3. SONG D, Hu Y, Diao B, Miao R, et al
    Effects of Tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast Cancer.
    BMC Cancer. 2021;21:798.
    PubMed     Abstract available

  4. NAKAYAMA T, Yoshinami T, Yasojima H, Kittaka N, et al
    Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917).
    BMC Cancer. 2021;21:795.
    PubMed     Abstract available

    June 2021
  5. JIAO X, Wang B, Feng C, Song S, et al
    Formin-like protein 2 promotes cell proliferation by a p27-related mechanism in human breast cancer cells.
    BMC Cancer. 2021;21:760.
    PubMed     Abstract available

  6. ZHAO Q, Hughes R, Neupane B, Mickle K, et al
    Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer.
    BMC Cancer. 2021;21:758.
    PubMed     Abstract available

  7. GAO J, Wang S, Zhang Z, Li J, et al
    Long non-coding RNA BRE-AS1 inhibits the proliferation, migration, and invasion of cancer cells in triple-negative breast cancer and predicts patients' survival by downregulating miR-21.
    BMC Cancer. 2021;21:745.
    PubMed     Abstract available

  8. HE C, Zhu WX, Tang Y, Bai Y, et al
    Knowledge of a cancer diagnosis is a protective factor for the survival of patients with breast cancer: a retrospective cohort study.
    BMC Cancer. 2021;21:739.
    PubMed     Abstract available

  9. WANG K, Jin X, Wang W, Yu X, et al
    The role of postmastectomy radiation in patients with ypN0 breast cancer after neoadjuvant chemotherapy: a meta-analysis.
    BMC Cancer. 2021;21:728.
    PubMed     Abstract available

  10. HALLER H, Voiss P, Cramer H, Paul A, et al
    The INTREST registry: protocol of a multicenter prospective cohort study of predictors of women's response to integrative breast cancer treatment.
    BMC Cancer. 2021;21:724.
    PubMed     Abstract available

  11. GUO L, Xie G, Wang R, Yang L, et al
    Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy?
    BMC Cancer. 2021;21:717.
    PubMed     Abstract available

  12. DONG J, Sun Q, Pan Y, Lu N, et al
    Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy.
    BMC Cancer. 2021;21:700.
    PubMed     Abstract available

  13. SUN M, Tang C, Liu J, Jiang W, et al
    Comprehensive analysis of suppressor of cytokine signaling proteins in human breast Cancer.
    BMC Cancer. 2021;21:696.
    PubMed     Abstract available

  14. BREIDENBACH C, Wesselmann S, Sibert NT, Ortmann O, et al
    Use of social service counseling by cancer patients: an analysis of quality assurance data of 6339 breast cancer patients from 13 certified centers in Germany treated between 2015 and 2017.
    BMC Cancer. 2021;21:671.
    PubMed     Abstract available

  15. BORRERO-GARCIA LD, Del Mar Maldonado M, Medina-Velazquez J, Troche-Torres AL, et al
    Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
    BMC Cancer. 2021;21:652.
    PubMed     Abstract available

    May 2021
  16. WOO J, Oh SJ, Song JY, Chae BJ, et al
    Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: a large, multicenter, observational study.
    BMC Cancer. 2021;21:647.
    PubMed     Abstract available

  17. HUANG S, Hu P, Lakowski TM
    Predicting breast cancer drug response using a multiple-layer cell line drug response network model.
    BMC Cancer. 2021;21:648.
    PubMed     Abstract available

  18. WANG D, Wei G, Ma J, Cheng S, et al
    Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients.
    BMC Cancer. 2021;21:645.
    PubMed     Abstract available

  19. FOSTER M, Niedzwiedz CL
    Associations between multimorbidity and depression among breast cancer survivors within the UK Biobank cohort: a cross-sectional study.
    BMC Cancer. 2021;21:650.
    PubMed     Abstract available

  20. LIU Y, Teng L, Fu S, Wang G, et al
    Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
    BMC Cancer. 2021;21:644.
    PubMed     Abstract available

  21. MCWILLIAMS L, Woof VG, Donnelly LS, Howell A, et al
    Extending screening intervals for women at low risk of breast cancer: do they find it acceptable?
    BMC Cancer. 2021;21:637.
    PubMed     Abstract available

  22. CHOI SH, Yoon HS, Yoo SA, Yun SH, et al
    Co-relation with novel phosphorylation sites of IkappaBalpha and necroptosis in breast cancer cells.
    BMC Cancer. 2021;21:596.
    PubMed     Abstract available

  23. ANWAR SL, Cahyono R, Prabowo D, Avanti WS, et al
    Metabolic comorbidities and the association with risks of recurrent metastatic disease in breast cancer survivors.
    BMC Cancer. 2021;21:590.
    PubMed     Abstract available

  24. HAN P, Zhu J, Feng G, Wang Z, et al
    Characterization of alternative splicing events and prognostic signatures in breast cancer.
    BMC Cancer. 2021;21:587.
    PubMed     Abstract available

  25. ZOGRAFOS E, Korakiti AM, Andrikopoulou A, Rellias I, et al
    Germline mutations in a clinic-based series of pregnancy associated breast cancer patients.
    BMC Cancer. 2021;21:572.
    PubMed     Abstract available

  26. ZHANG Y, Asad S, Weber Z, Tallman D, et al
    Genomic features of rapid versus late relapse in triple negative breast cancer.
    BMC Cancer. 2021;21:568.
    PubMed     Abstract available

  27. CHAN CWH, Law BMH, Ng MSN, Wong CCY, et al
    Association of single nucleotide polymorphisms of cytochrome P450 enzymes with experience of vasomotor, vaginal and musculoskeletal symptoms among breast cancer patients: a systematic review.
    BMC Cancer. 2021;21:570.
    PubMed     Abstract available

  28. ZHANG M, Wang B, Liu N, Wang H, et al
    Nomogram for predicting preoperative regional lymph nodes metastasis in patients with metaplastic breast cancer: a SEER population-based study.
    BMC Cancer. 2021;21:565.
    PubMed     Abstract available

  29. NITTALA MR, Mundra EK, Packianathan S, Mehta D, et al
    The Will Rogers phenomenon, breast cancer and race.
    BMC Cancer. 2021;21:554.
    PubMed     Abstract available

  30. MILLS MN, Naz A, Thawani C, Walker C, et al
    Capecitabine and stereotactic radiation in the management of breast cancer brain metastases.
    BMC Cancer. 2021;21:552.
    PubMed     Abstract available

  31. WANG Y, Wang Y, Chen R, Tang Z, et al
    Plasma fibrinogen acts as a predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer: a retrospective study of 1004 Chinese breast cancer patients.
    BMC Cancer. 2021;21:542.
    PubMed     Abstract available

  32. SOOD R, Masalu N, Connolly RM, Chao CA, et al
    Invasive breast Cancer treatment in Tanzania: landscape assessment to prepare for implementation of standardized treatment guidelines.
    BMC Cancer. 2021;21:527.
    PubMed     Abstract available

  33. WANG B, Wang H, Zhao A, Zhang M, et al
    Poor prognosis of male triple-positive breast Cancer patients: a propensity score matched SEER analysis and molecular portraits.
    BMC Cancer. 2021;21:523.
    PubMed     Abstract available

  34. WANG C, Hu K, Deng L, He W, et al
    Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy.
    BMC Cancer. 2021;21:491.
    PubMed     Abstract available

  35. WOODS LM, Rachet B, Morris M, Bhaskaran K, et al
    Are socio-economic inequalities in breast cancer survival explained by peri-diagnostic factors?
    BMC Cancer. 2021;21:485.
    PubMed     Abstract available

  36. EOM KY, van Londen GJ, Li J, Dahman B, et al
    Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform.
    BMC Cancer. 2021;21:487.
    PubMed     Abstract available

    April 2021
  37. YUAN Y, Xiao WW, Xie WH, Li RZ, et al
    Prognostic value of ubiquitin E2 UBE2W and its correlation with tumor-infiltrating immune cells in breast cancer.
    BMC Cancer. 2021;21:479.
    PubMed     Abstract available

  38. YAMAMURA J, Kamigaki S, Fujita J, Osato H, et al
    New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
    BMC Cancer. 2021;21:476.
    PubMed     Abstract available

  39. MAJED SO, Mustafa SA
    MACE-Seq-based coding RNA and TrueQuant-based small RNA profile in breast cancer: tumor-suppressive miRNA-1275 identified as a novel marker.
    BMC Cancer. 2021;21:473.
    PubMed     Abstract available

  40. YU Y, Wang Z, Wei Z, Yu B, et al
    Development and validation of nomograms for predicting axillary non-SLN metastases in breast cancer patients with 1-2 positive sentinel lymph node macro-metastases: a retrospective analysis of two independent cohorts.
    BMC Cancer. 2021;21:466.
    PubMed     Abstract available

  41. LIU H, Shi W, Jin Z, Zhuo R, et al
    Global, regional, and national mortality trends of female breast cancer by risk factor, 1990-2017.
    BMC Cancer. 2021;21:459.
    PubMed     Abstract available

  42. NAJAFI S, Ansari M, Kaveh V, Haghighat S, et al
    Comparing the efficacy and side-effects of PDLASTA(R) (Pegfilgrastim) with PDGRASTIM(R) (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial.
    BMC Cancer. 2021;21:454.
    PubMed     Abstract available

  43. HOUSE BJ, Kwon MJ, Schaefer JM, Barth CW, et al
    Clinically relevant dual probe difference specimen imaging (DDSI) protocol for freshly resected breast cancer specimen staining.
    BMC Cancer. 2021;21:440.
    PubMed     Abstract available

  44. JANEVA S, Parris TZ, Nasic S, De Lara S, et al
    Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens.
    BMC Cancer. 2021;21:439.
    PubMed     Abstract available

  45. YAMAGUCHI J, Moriuchi H, Ueda T, Kawashita Y, et al
    Active behavior of triple-negative breast cancer with adipose tissue invasion: a single center and retrospective review.
    BMC Cancer. 2021;21:434.
    PubMed     Abstract available

  46. TAN Z, Zou Y, Zhu M, Luo Z, et al
    Carnitine palmitoyl transferase 1A is a novel diagnostic and predictive biomarker for breast cancer.
    BMC Cancer. 2021;21:409.
    PubMed     Abstract available

  47. LV R, Yang G, Huang Y, Wang Y, et al
    Dosimetric effects of supine immobilization devices on the skin in intensity-modulated radiation therapy for breast cancer: a retrospective study.
    BMC Cancer. 2021;21:384.
    PubMed     Abstract available

  48. LIANG G, Ma W, Zhao Y, Liu E, et al
    Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters.
    BMC Cancer. 2021;21:362.
    PubMed     Abstract available

  49. LIU Z, Liu J, Liu R, Xue M, et al
    Downregulated ZNF132 predicts unfavorable outcomes in breast Cancer via Hypermethylation modification.
    BMC Cancer. 2021;21:367.
    PubMed     Abstract available

  50. REECE JC, Neal EFG, Nguyen P, McIntosh JG, et al
    Delayed or failure to follow-up abnormal breast cancer screening mammograms in primary care: a systematic review.
    BMC Cancer. 2021;21:373.
    PubMed     Abstract available

  51. AREFAN D, Hausler RM, Sumkin JH, Sun M, et al
    Predicting cell invasion in breast tumor microenvironment from radiological imaging phenotypes.
    BMC Cancer. 2021;21:370.
    PubMed     Abstract available

  52. CABIOGLU N, Onder S, Oner G, Karatay H, et al
    TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer.
    BMC Cancer. 2021;21:357.
    PubMed     Abstract available

    March 2021
  53. COLOMBIE M, Jezequel P, Rubeaux M, Frenel JS, et al
    The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients.
    BMC Cancer. 2021;21:333.
    PubMed     Abstract available

  54. CHEN S, Han Y, Ouyang Q, Lu J, et al
    Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy.
    BMC Cancer. 2021;21:341.
    PubMed     Abstract available

  55. CHU CN, Hu KC, Wu RS, Bau DT, et al
    Radiation-irritated skin and hyperpigmentation may impact the quality of life of breast cancer patients after whole breast radiotherapy.
    BMC Cancer. 2021;21:330.
    PubMed     Abstract available

  56. CHEN L, Dong Y, Pan Y, Zhang Y, et al
    Identification and development of an independent immune-related genes prognostic model for breast cancer.
    BMC Cancer. 2021;21:329.
    PubMed     Abstract available

  57. FALCICCHIO C, Di Lallo D, Fabi A, Bonucci A, et al
    Use of rehabilitation pathways in women with breast cancer in the first 12 months of the disease: a retrospective study.
    BMC Cancer. 2021;21:311.
    PubMed     Abstract available

  58. ALOMRAN R, White M, Bruce M, Bressel M, et al
    Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR).
    BMC Cancer. 2021;21:303.
    PubMed     Abstract available

  59. SANDVEI MS, Opdahl S, Valla M, Lagiou P, et al
    The association of women's birth size with risk of molecular breast cancer subtypes: a cohort study.
    BMC Cancer. 2021;21:299.
    PubMed     Abstract available

  60. JAYASINGHE R, Fernando A, Jayarajah U, Seneviratne S, et al
    Post treatment quality of life among Sri Lankan women with breast cancer.
    BMC Cancer. 2021;21:305.
    PubMed     Abstract available

  61. YUAN Q, Hou J, He Y, Liao Y, et al
    Minimize the extent and morbidity of axillary dissection for node-positive breast cancer patients: implementation of axillary lymph node dissection based on breast lymphatics level.
    BMC Cancer. 2021;21:293.
    PubMed     Abstract available

  62. KURODA H, Jamiyan T, Yamaguchi R, Kakumoto A, et al
    Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast.
    BMC Cancer. 2021;21:286.
    PubMed     Abstract available

  63. LIN B, Liu C, Shi E, Jin Q, et al
    MiR-105-3p acts as an oncogene to promote the proliferation and metastasis of breast cancer cells by targeting GOLIM4.
    BMC Cancer. 2021;21:275.
    PubMed     Abstract available

  64. ZEPPELLINI A, Galimberti S, Leone BE, Pacifico C, et al
    Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study.
    BMC Cancer. 2021;21:260.
    PubMed     Abstract available

  65. SATO A, Matsubayashi K, Morishima T, Nakata K, et al
    Increasing trends in the prevalence of prior cancer in newly diagnosed lung, stomach, colorectal, breast, cervical, and corpus uterine cancer patients: a population-based study.
    BMC Cancer. 2021;21:264.
    PubMed     Abstract available

  66. LI C, Tao C, Bai T, Li Z, et al
    Beam complexity and monitor unit efficiency comparison in two different volumetric modulated arc therapy delivery systems using automated planning.
    BMC Cancer. 2021;21:261.
    PubMed     Abstract available

  67. JI L, Cheng L, Zhu X, Gao Y, et al
    Risk and prognostic factors of breast cancer with liver metastases.
    BMC Cancer. 2021;21:238.
    PubMed     Abstract available

  68. YOSHIKAWA K, Ishida M, Yanai H, Tsuta K, et al
    Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer.
    BMC Cancer. 2021;21:239.
    PubMed     Abstract available

  69. HERRMANN C, Morant R, Walser E, Mousavi M, et al
    Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects.
    BMC Cancer. 2021;21:229.
    PubMed     Abstract available

  70. WIND A, Hartman ED, Van Eekeren RRJP, Wijn RPWF, et al
    Validating a generic cancer consumer quality index in eight European countries, patient reported experiences and the influence of cultural differences.
    BMC Cancer. 2021;21:231.
    PubMed     Abstract available

  71. LIU X, Zheng D, Wu Y, Luo C, et al
    Treatment patterns and outcomes in older women with early breast cancer: a population-based cohort study in China.
    BMC Cancer. 2021;21:226.
    PubMed     Abstract available

  72. HUANG Z, Zhou X, Tong Y, Zhu L, et al
    Surgery for primary tumor benefits survival for breast cancer patients with bone metastases: a large cohort retrospective study.
    BMC Cancer. 2021;21:222.
    PubMed     Abstract available

  73. MILLS MN, Walker C, Thawani C, Naz A, et al
    Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.
    BMC Cancer. 2021;21:223.
    PubMed     Abstract available

  74. TOPNO R, Singh I, Kumar M, Agarwal P, et al
    Integrated bioinformatic analysis identifies UBE2Q1 as a potential prognostic marker for high grade serous ovarian cancer.
    BMC Cancer. 2021;21:220.
    PubMed     Abstract available

  75. WONG SK, Hamm J, Shokoohi A, McGahan CE, et al
    Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment.
    BMC Cancer. 2021;21:215.
    PubMed     Abstract available

  76. ZHANG SL, Song J, Wang YR, Guo YJ, et al
    Short-term outcomes and safety of radiotherapy for immediate breast reconstruction with autologous flap transfer following breast-conserving surgery.
    BMC Cancer. 2021;21:214.
    PubMed     Abstract available

  77. OLOW AK, Veer LV', Wolf DM
    Toward developing a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments.
    BMC Cancer. 2021;21:212.
    PubMed     Abstract available

    February 2021
  78. ZHAO F, Hao Z, Zhong Y, Xu Y, et al
    Discovery of breast cancer risk genes and establishment of a prediction model based on estrogen metabolism regulation.
    BMC Cancer. 2021;21:194.
    PubMed     Abstract available

  79. YU L, Shi Q, Jin Y, Liu Z, et al
    Blockage of AMPK-ULK1 pathway mediated autophagy promotes cell apoptosis to increase doxorubicin sensitivity in breast cancer (BC) cells: an in vitro study.
    BMC Cancer. 2021;21:195.
    PubMed     Abstract available

  80. HUANG CC, Tsai YF, Liu CY, Chao TC, et al
    Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
    BMC Cancer. 2021;21:199.
    PubMed     Abstract available

  81. MATSON DR, Denu RA, Zasadil LM, Burkard ME, et al
    High nuclear TPX2 expression correlates with TP53 mutation and poor clinical behavior in a large breast cancer cohort, but is not an independent predictor of chromosomal instability.
    BMC Cancer. 2021;21:186.
    PubMed     Abstract available

  82. TSUJI K, Matsuoka YJ, Ochi E
    High-intensity interval training in breast cancer survivors: a systematic review.
    BMC Cancer. 2021;21:184.
    PubMed     Abstract available

  83. BERGER K, Rhost S, Rafnsdottir S, Hughes E, et al
    Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer.
    BMC Cancer. 2021;21:185.
    PubMed     Abstract available

  84. JIANG H, Li H
    Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:149.
    PubMed     Abstract available

  85. TAN W, Liu M, Wang L, Guo Y, et al
    Novel immune-related genes in the tumor microenvironment with prognostic value in breast cancer.
    BMC Cancer. 2021;21:126.
    PubMed     Abstract available

  86. LIU M, Liu S, Yang L, Wang S, et al
    Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:118.
    PubMed     Abstract available

  87. THUREAU S, Marchesi V, Vieillard MH, Perrier L, et al
    Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase II
    BMC Cancer. 2021;21:117.
    PubMed     Abstract available

  88. YANG Q, Zhong X, Zhang W, Luo T, et al
    Cost-effectiveness of different surgical treatment approaches for early breast cancer: a retrospective matched cohort study from China.
    BMC Cancer. 2021;21:107.
    PubMed     Abstract available

  89. KAWAMOTO T, Shikama N, Kurokawa C, Hara N, et al
    A prospective feasibility study of a 1-mm bolus for postmastectomy radiotherapy.
    BMC Cancer. 2021;21:109.
    PubMed     Abstract available

    January 2021
  90. BEACHLER DC, de Luise C, Jamal-Allial A, Yin R, et al
    Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study.
    BMC Cancer. 2021;21:97.
    PubMed     Abstract available

  91. WHITEHEAD I, Irwin GW, Bannon F, Coles CE, et al
    The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making.
    BMC Cancer. 2021;21:90.
    PubMed     Abstract available

  92. JUNG SM, Jeon BJ, Woo J, Ryu JM, et al
    Does chemotherapy or radiotherapy affect the postoperative complication in breast cancer patients who underwent immediate breast reconstruction with tissue expander?
    BMC Cancer. 2021;21:88.
    PubMed     Abstract available

  93. HUO X, Li J, Zhao F, Ren D, et al
    The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:78.
    PubMed     Abstract available

  94. EVANGELISTA AF, Oliveira RJ, O Silva VA, D C Vieira RA, et al
    Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
    BMC Cancer. 2021;21:76.
    PubMed     Abstract available

  95. BASET Z, Abdul-Ghafar J, Parpio YN, Haidary AM, et al
    Risk factors of breast cancer among patients in a tertiary care hospitals in Afghanistan: a case control study.
    BMC Cancer. 2021;21:71.
    PubMed     Abstract available

  96. GENG SK, Fu SM, Ma SH, Fu YP, et al
    Tumor infiltrating neutrophil might play a major role in predicting the clinical outcome of breast cancer patients treated with neoadjuvant chemotherapy.
    BMC Cancer. 2021;21:68.
    PubMed     Abstract available

  97. OO KK, Kamolhan T, Soni A, Thongchot S, et al
    Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer.
    BMC Cancer. 2021;21:65.
    PubMed     Abstract available

  98. FIROUZABADI D, Dehghanian A, Rezvani A, Mahmoudi L, et al
    Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.
    BMC Cancer. 2021;21:47.
    PubMed     Abstract available

  99. NAKATSUKASA K, Niikura N, Kashiwabara K, Amemiya T, et al
    Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC.
    BMC Cancer. 2021;21:34.
    PubMed     Abstract available

  100. MOSLEMI M, Moradi Y, Dehghanbanadaki H, Afkhami H, et al
    The association between ATM variants and risk of breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:27.
    PubMed     Abstract available

    December 2020
  101. GOTO W, Kashiwagi S, Asano Y, Takada K, et al
    Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
    BMC Cancer. 2020;20:1215.
    PubMed     Abstract available

  102. DESA DE, Strawderman RL, Wu W, Hill RL, et al
    Intratumoral heterogeneity of second-harmonic generation scattering from tumor collagen and its effects on metastatic risk prediction.
    BMC Cancer. 2020;20:1217.
    PubMed     Abstract available

  103. KIM JY, Jung EJ, Kim JM, Lee HS, et al
    Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis.
    BMC Cancer. 2020;20:1206.
    PubMed     Abstract available

  104. BAO H, Wang L, Brown M, Zhang M, et al
    A nationally quasi-experimental study to assess the impact of partial organized breast and cervical cancer screening programme on participation and inequalities.
    BMC Cancer. 2020;20:1191.
    PubMed     Abstract available

  105. KROZ M, Reif M, Glinz A, Berger B, et al
    Correction to: Impact of a combined multimodal-aerobic and multimodal intervention compared to standard aerobic treatment in breast cancer survivors with chronic cancer-related fatigue - results of a three-armed pragmatic trial in a comprehensive coho
    BMC Cancer. 2020;20:1174.
    PubMed     Abstract available

  106. TORRES-ROMAN JS, Martinez-Herrera JF, Carioli G, Ybaseta-Medina J, et al
    Breast cancer mortality trends in Peruvian women.
    BMC Cancer. 2020;20:1173.
    PubMed     Abstract available

    November 2020
  107. BISWAS A, Mukherjee G, Kondaiah P, Desai KV, et al
    Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer.
    BMC Cancer. 2020;20:1159.
    PubMed     Abstract available

  108. SUN GY, Wen G, Zhang YJ, Tang Y, et al
    Radiotherapy plays an important role in improving the survival outcome in patients with T1-2N1M0 breast cancer - a joint analysis of 4262 real world cases from two institutions.
    BMC Cancer. 2020;20:1155.
    PubMed     Abstract available

  109. ZHANG Z, Zheng Q, Liu Y, Sun L, et al
    Human CD133-positive hematopoietic progenitor cells enhance the malignancy of breast cancer cells.
    BMC Cancer. 2020;20:1158.
    PubMed     Abstract available

  110. GAO ZH, Li CX, Liu M, Jiang JY, et al
    Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
    BMC Cancer. 2020;20:1150.
    PubMed     Abstract available

  111. ZHANG L, Tang R, Deng JP, Zhang WW, et al
    The effect of postmastectomy radiotherapy in node-positive triple-negative breast cancer.
    BMC Cancer. 2020;20:1146.
    PubMed     Abstract available

  112. WANG J, Tang Y, Jing H, Sun G, et al
    Risk stratification for prediction of locoregional recurrence in patients with pathologic T1-2N0 breast cancer after mastectomy.
    BMC Cancer. 2020;20:1132.
    PubMed     Abstract available

  113. BERGER E, Maitre N, Romana Mancini F, Baglietto L, et al
    The impact of lifecourse socio-economic position and individual social mobility on breast cancer risk.
    BMC Cancer. 2020;20:1138.
    PubMed     Abstract available

  114. SHIRMOHAMMADI E, Ebrahimi SS, Farshchi A, Salimi M, et al
    Correction to: The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages.
    BMC Cancer. 2020;20:1126.
    PubMed     Abstract available

  115. KAPLAN HG, Malmgren JA, Atwood MK
    Breast cancer distant recurrence lead time interval by detection method in an institutional cohort.
    BMC Cancer. 2020;20:1124.
    PubMed     Abstract available

  116. MARINELLI O, Romagnoli E, Maggi F, Nabissi M, et al
    Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER(+)HER2(-)Rb wild-type and knock-down in breast cancer cell lines.
    BMC Cancer. 2020;20:1119.
    PubMed     Abstract available

  117. PU S, Wang K, Liu Y, Liao X, et al
    Nomogram-derived prediction of pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NCT).
    BMC Cancer. 2020;20:1120.
    PubMed     Abstract available

  118. REZNICZEK GA, Giger-Pabst U, Thaher O, Tempfer CB, et al
    Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for rare gynecologic indications: peritoneal metastases from breast and endometrial cancer.
    BMC Cancer. 2020;20:1122.
    PubMed     Abstract available

  119. LEE IH, Lee SJ, Lee J, Jung JH, et al
    Utility of (18)F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy.
    BMC Cancer. 2020;20:1106.
    PubMed     Abstract available

  120. LI X, Zhang X, Liu J, Shen Y, et al
    Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    BMC Cancer. 2020;20:1102.
    PubMed     Abstract available

  121. FENG R, Jing J, Zhang X, Li M, et al
    Adherence to post-surgery follow-up assessment and its association with sociodemographic and disease characteristics in patients with breast cancer in Central China.
    BMC Cancer. 2020;20:1098.
    PubMed     Abstract available

  122. PITTALIS C, Panteli E, Schouten E, Magongwa I, et al
    Breast and cervical cancer screening services in Malawi: a systematic review.
    BMC Cancer. 2020;20:1101.
    PubMed     Abstract available

  123. HERNANDEZ VARGAS JA, Ramirez Barbosa PX, Gil Quijano AM, Valbuena AM, et al
    Patterns of breast, prostate and cervical cancer incidence and mortality in Colombia: an administrative registry data analysis.
    BMC Cancer. 2020;20:1097.
    PubMed     Abstract available

  124. NG CWQ, Lim JNW, Liu J, Hartman M, et al
    Presentation of breast cancer, help seeking behaviour and experience of patients in their cancer journey in Singapore: a qualitative study.
    BMC Cancer. 2020;20:1080.
    PubMed     Abstract available

  125. MALIK R, Vera N, Dayal C, Choudhari A, et al
    Factors associated with breast cancer awareness and breast self-examination in Fiji and Kashmir India - a cross-sectional study.
    BMC Cancer. 2020;20:1078.
    PubMed     Abstract available

  126. RING A, Kaur P, Lang JE
    EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    BMC Cancer. 2020;20:1076.
    PubMed     Abstract available

  127. TRIVINO JC, Ceba A, Rubio-Solsona E, Serra D, et al
    Combination of phenotype and polygenic risk score in breast cancer risk evaluation in the Spanish population: a case -control study.
    BMC Cancer. 2020;20:1079.
    PubMed     Abstract available

  128. MUNOZ-ALCARAZ MN, Perula-de-Torres LA, Serrano-Merino J, Jimenez-Vilchez AJ, et al
    Efficacy and efficiency of a new therapeutic approach based on activity-oriented proprioceptive antiedema therapy (TAPA) for edema reduction and improved occupational performance in the rehabilitation of breast cancer-related arm lymphedema in women:
    BMC Cancer. 2020;20:1074.
    PubMed     Abstract available

  129. NI M, Zhou X, Liu J, Yu H, et al
    Prediction of the clinicopathological subtypes of breast cancer using a fisher discriminant analysis model based on radiomic features of diffusion-weighted MRI.
    BMC Cancer. 2020;20:1073.
    PubMed     Abstract available

  130. YANAI K, Fujii T, Horiguchi J, Nakazawa Y, et al
    Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer.
    BMC Cancer. 2020;20:1068.
    PubMed     Abstract available

  131. TENTLER JJ, Lang J, Capasso A, Kim DJ, et al
    RX-5902, a novel beta-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
    BMC Cancer. 2020;20:1063.
    PubMed     Abstract available

  132. LIM GB, Kim YA, Seo JH, Lee HJ, et al
    Prediction of prognostic signatures in triple-negative breast cancer based on the differential expression analysis via NanoString nCounter immune panel.
    BMC Cancer. 2020;20:1052.
    PubMed     Abstract available

  133. KWONG A, Shin VY, Ho CYS, Au CH, et al
    Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients.
    BMC Cancer. 2020;20:1053.
    PubMed     Abstract available

  134. XU H, Liu Z, Shi H, Wang C, et al
    Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:1051.
    PubMed     Abstract available

    October 2020
  135. ENNOUR-IDRISSI K, Dragic D, Durocher F, Diorio C, et al
    Epigenome-wide DNA methylation and risk of breast cancer: a systematic review.
    BMC Cancer. 2020;20:1048.
    PubMed     Abstract available

  136. SHAMSHIRIAN A, Aref AR, Yip GW, Ebrahimi Warkiani M, et al
    Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:1049.
    PubMed     Abstract available

  137. WEI C, Li X
    Verteporfin inhibits cell proliferation and induces apoptosis in different subtypes of breast cancer cell lines without light activation.
    BMC Cancer. 2020;20:1042.
    PubMed     Abstract available

  138. LEI YY, Ho SC, Kwok C, Cheng A, et al
    Longitudinal changes in sports activity from pre-diagnosis to first five years post-diagnosis: a prospective Chinese breast cancer cohort study.
    BMC Cancer. 2020;20:1013.
    PubMed     Abstract available

  139. AGBEKO AE, Arthur J, Bayuo J, Kaburi BB, et al
    Seeking healthcare at their 'right' time; the iterative decision process for women with breast cancer.
    BMC Cancer. 2020;20:1011.
    PubMed     Abstract available

  140. MA T, Liu H, Liu Y, Liu T, et al
    USP6NL mediated by LINC00689/miR-142-3p promotes the development of triple-negative breast cancer.
    BMC Cancer. 2020;20:998.
    PubMed     Abstract available

  141. LI X, Zhou C, Wu Y, Chen X, et al
    Relationship between formulaic breast volume and risk of breast cancer based on linear measurements.
    BMC Cancer. 2020;20:989.
    PubMed     Abstract available

  142. ZHAO W, Wu L, Zhao A, Zhang M, et al
    A nomogram for predicting survival in patients with de novo metastatic breast cancer: a population-based study.
    BMC Cancer. 2020;20:982.
    PubMed     Abstract available

  143. RAINEY L, van der Waal D, Broeders MJM
    Dutch women's intended participation in a risk-based breast cancer screening and prevention programme: a survey study identifying preferences, facilitators and barriers.
    BMC Cancer. 2020;20:965.
    PubMed     Abstract available

  144. XIA L, Li F, Qiu J, Feng Z, et al
    Oncogenic miR-20b-5p contributes to malignant behaviors of breast cancer stem cells by bidirectionally regulating CCND1 and E2F1.
    BMC Cancer. 2020;20:949.
    PubMed     Abstract available

  145. CULBERTSON MG, Bennett K, Kelly CM, Sharp L, et al
    The psychosocial determinants of quality of life in breast cancer survivors: a scoping review.
    BMC Cancer. 2020;20:948.
    PubMed     Abstract available

  146. NIU S, Huang J, Li J, Liu X, et al
    Application of ultrasound artificial intelligence in the differential diagnosis between benign and malignant breast lesions of BI-RADS 4A.
    BMC Cancer. 2020;20:959.
    PubMed     Abstract available

  147. AKAHANE T, Kanomata N, Harada O, Yamashita T, et al
    Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
    BMC Cancer. 2020;20:944.
    PubMed     Abstract available

    September 2020
  148. LEE J, Jung JH, Kim WW, Park CS, et al
    Efficacy of breast MRI for surgical decision in patients with breast cancer: ductal carcinoma in situ versus invasive ductal carcinoma.
    BMC Cancer. 2020;20:934.
    PubMed     Abstract available

  149. INARI H, Teruya N, Kishi M, Horii R, et al
    Clinicopathological features of breast cancer patients with internal mammary and/or supraclavicular lymph node recurrence without distant metastasis.
    BMC Cancer. 2020;20:932.
    PubMed     Abstract available

  150. FUJITA M, Imadome K, Somasundaram V, Kawanishi M, et al
    Metabolic characterization of aggressive breast cancer cells exhibiting invasive phenotype: impact of non-cytotoxic doses of 2-DG on diminishing invasiveness.
    BMC Cancer. 2020;20:929.
    PubMed     Abstract available

  151. YANG H, Xu Y, Zhao Y, Yin J, et al
    The role of tissue elasticity in the differential diagnosis of benign and malignant breast lesions using shear wave elastography.
    BMC Cancer. 2020;20:930.
    PubMed     Abstract available

  152. MURILLO-ORTIZ B, Hernandez-Ramirez A, Rivera-Villanueva T, Suarez-Garcia D, et al
    Monofrequency electrical impedance mammography (EIM) diagnostic system in breast cancer screening.
    BMC Cancer. 2020;20:876.
    PubMed     Abstract available

  153. CAI YC, Yang H, Wang KF, Chen TH, et al
    ANGPTL4 overexpression inhibits tumor cell adhesion and migration and predicts favorable prognosis of triple-negative breast cancer.
    BMC Cancer. 2020;20:878.
    PubMed     Abstract available

  154. DAVIE A, Carter GC, Rider A, Pike J, et al
    Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries.
    BMC Cancer. 2020;20:855.
    PubMed     Abstract available

  155. BAKSHI D, Nagpal A, Sharma V, Sharma I, et al
    MassARRAY-based single nucleotide polymorphism analysis in breast cancer of north Indian population.
    BMC Cancer. 2020;20:861.
    PubMed     Abstract available

  156. BAKKACH J, Mansouri M, Derkaoui T, Loudiyi A, et al
    Contribution of BRCA1 and BRCA2 germline mutations to early onset breast cancer: a series from north of Morocco.
    BMC Cancer. 2020;20:859.
    PubMed     Abstract available

  157. SCHWEDHELM TM, Rees JR, Onega T, Zipkin RJ, et al
    Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
    BMC Cancer. 2020;20:847.
    PubMed     Abstract available

  158. SHIRMOHAMMADI E, Ebrahimi SS, Farshchi A, Salimi M, et al
    The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages.
    BMC Cancer. 2020;20:836.
    PubMed     Abstract available

  159. JIANG H, Li X, Wang W, Dong H, et al
    Long non-coding RNA SNHG3 promotes breast cancer cell proliferation and metastasis by binding to microRNA-154-3p and activating the notch signaling pathway.
    BMC Cancer. 2020;20:838.
    PubMed     Abstract available

    August 2020
  160. WANG S, Wen G, Tang Y, Yang Y, et al
    Effectiveness of the AJCC 8th edition staging system for selecting patients with T1-2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions.
    BMC Cancer. 2020;20:792.
    PubMed     Abstract available

  161. MURATOV S, Canelo-Aybar C, Tarride JE, Alonso-Coello P, et al
    Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators.
    BMC Cancer. 2020;20:795.
    PubMed     Abstract available

  162. HICKS BM, Busby J, Mills K, O'Neil FA, et al
    Post-diagnostic antipsychotic use and cancer mortality: a population based cohort study.
    BMC Cancer. 2020;20:804.
    PubMed     Abstract available

  163. PARE M, Darini CY, Yao X, Chignon-Sicard B, et al
    Breast cancer mammospheres secrete Adrenomedullin to induce lipolysis and browning of adjacent adipocytes.
    BMC Cancer. 2020;20:784.
    PubMed     Abstract available

  164. TOOHEY K, Pumpa K, McKune A, Cooke J, et al
    The impact of high-intensity interval training exercise on breast cancer survivors: a pilot study to explore fitness, cardiac regulation and biomarkers of the stress systems.
    BMC Cancer. 2020;20:787.
    PubMed     Abstract available

  165. ALEXEEV SM, Khorinko AV, Mukhametshina GZ, Shelepen KG, et al
    Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab.
    BMC Cancer. 2020;20:783.
    PubMed     Abstract available

  166. ZHONG L, Xie L, Yang Z, Li L, et al
    Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers.
    BMC Cancer. 2020;20:766.
    PubMed     Abstract available

  167. MUZZATTI B, Bomben F, Flaiban C, Piccinin M, et al
    Quality of life and psychological distress during cancer: a prospective observational study involving young breast cancer female patients.
    BMC Cancer. 2020;20:758.
    PubMed     Abstract available

  168. DU X, Todorov P, Isachenko E, Rahimi G, et al
    Increasing of malignancy of breast cancer cells after cryopreservation: molecular detection and activation of angiogenesis after CAM-xenotransplantation.
    BMC Cancer. 2020;20:753.
    PubMed     Abstract available

  169. MAAYAH ZH, Takahara S, Alam AS, Ferdaoussi M, et al
    Breast cancer diagnosis is associated with relative left ventricular hypertrophy and elevated endothelin-1 signaling.
    BMC Cancer. 2020;20:751.
    PubMed     Abstract available

  170. SHAO C, Yu Z, Xiao J, Liu L, et al
    Prognosis of pregnancy-associated breast cancer: a meta-analysis.
    BMC Cancer. 2020;20:746.
    PubMed     Abstract available

  171. GOVINDAN S, Siraganahalli Eswaraiah M, Basavaraj C, Adinarayan M, et al
    Androgen Receptor mRNA levels determine the prognosis in triple-negative breast cancer patients.
    BMC Cancer. 2020;20:745.
    PubMed     Abstract available

  172. EL ANSARI FZ, Jouali F, Marchoudi N, Bennani MM, et al
    Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
    BMC Cancer. 2020;20:747.
    PubMed     Abstract available

  173. WANG B, Lu Z, Huang Y, Li R, et al
    Does hypothyroidism increase the risk of breast cancer: evidence from a meta-analysis.
    BMC Cancer. 2020;20:733.
    PubMed     Abstract available

  174. GWYNNE WD, Shakeel MS, Girgis-Gabardo A, Kim KH, et al
    Antagonists of the serotonin receptor 5A target human breast tumor initiating cells.
    BMC Cancer. 2020;20:724.
    PubMed     Abstract available

    July 2020
  175. BRUNET J, Barrett-Bernstein M, Zadravec K, Taljaard M, et al
    Study protocol of the Aerobic exercise and CogniTIVe functioning in women with breAsT cancEr (ACTIVATE) trial: a two-arm, two-centre randomized controlled trial.
    BMC Cancer. 2020;20:711.
    PubMed     Abstract available

  176. GE A, Gao S, Liu Y, Zhang H, et al
    Methylation of WT1, CA10 in peripheral blood leukocyte is associated with breast cancer risk: a case-control study.
    BMC Cancer. 2020;20:713.
    PubMed     Abstract available

  177. HEIDARI Z, Mohammadi E, Aghamohammadi V, Jalali S, et al
    Dietary Approaches to Stop Hypertension (DASH) diets and breast cancer among women: a case control study.
    BMC Cancer. 2020;20:708.
    PubMed     Abstract available

  178. PENG C, DuPre N, VoPham T, Heng YJ, et al
    Low dose environmental radon exposure and breast tumor gene expression.
    BMC Cancer. 2020;20:695.
    PubMed     Abstract available

  179. TZANG BS, Chen VC, Hsieh CC, Wang WK, et al
    Differential associations of proinflammatory and anti-inflammatory cytokines with depression severity from noncancer status to breast cancer course and subsequent chemotherapy.
    BMC Cancer. 2020;20:686.
    PubMed     Abstract available

  180. MCWILLIAMS L, Woof VG, Donnelly LS, Howell A, et al
    Risk stratified breast cancer screening: UK healthcare policy decision-making stakeholders' views on a low-risk breast screening pathway.
    BMC Cancer. 2020;20:680.
    PubMed     Abstract available

  181. SOLEIMANI DODARAN M, Borgoni S, Sofyali E, Verschure PJ, et al
    Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
    BMC Cancer. 2020;20:676.
    PubMed     Abstract available

  182. REY-VARGAS L, Mejia-Henao JC, Sanabria-Salas MC, Serrano-Gomez SJ, et al
    Effect of neoadjuvant therapy on breast cancer biomarker profile.
    BMC Cancer. 2020;20:675.
    PubMed     Abstract available

  183. BELLAT V, Verchere A, Ashe SA, Law B, et al
    Transcriptomic insight into salinomycin mechanisms in breast cancer cell lines: synergistic effects with dasatinib and induction of estrogen receptor beta.
    BMC Cancer. 2020;20:661.
    PubMed     Abstract available

  184. HONG J, Huang J, Shen L, Zhu S, et al
    A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis.
    BMC Cancer. 2020;20:663.
    PubMed     Abstract available

  185. ZHENG Y, Wang M, Wang S, Xu P, et al
    LncRNA MEG3 rs3087918 was associated with a decreased breast cancer risk in a Chinese population: a case-control study.
    BMC Cancer. 2020;20:659.
    PubMed     Abstract available

  186. FOULKES SJ, Howden EJ, Antill Y, Loi S, et al
    Exercise as a diagnostic and therapeutic tool for preventing cardiovascular morbidity in breast cancer patients- the BReast cancer EXercise InTervention (BREXIT) trial protocol.
    BMC Cancer. 2020;20:655.
    PubMed     Abstract available

  187. WANG C, Lin Y, Zhou Y, Mao F, et al
    Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
    BMC Cancer. 2020;20:653.
    PubMed     Abstract available

  188. ZHU Y, Wang Q, Xia Y, Xiong X, et al
    Evaluation of MiR-1908-3p as a novel serum biomarker for breast cancer and analysis its oncogenic function and target genes.
    BMC Cancer. 2020;20:644.
    PubMed     Abstract available

  189. ABSIL L, Journe F, Larsimont D, Body JJ, et al
    Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cells.
    BMC Cancer. 2020;20:640.
    PubMed     Abstract available

  190. XIA B, Hou L, Kang H, Chang W, et al
    NR2F2 plays a major role in insulin-induced epithelial-mesenchymal transition in breast cancer cells.
    BMC Cancer. 2020;20:626.
    PubMed     Abstract available

  191. LU J, Zhang C, Han J, Xu Z, et al
    Starvation stress attenuates the miRNA-target interaction in suppressing breast cancer cell proliferation.
    BMC Cancer. 2020;20:627.
    PubMed     Abstract available

  192. WRIGHT CM, Halkett G, Carey Smith R, Moorin R, et al
    Sarcoma epidemiology and cancer-related hospitalisation in Western Australia from 1982 to 2016: a descriptive study using linked administrative data.
    BMC Cancer. 2020;20:625.
    PubMed     Abstract available

  193. DELRIEU L, Anota A, Tredan O, Freyssenet D, et al
    Design and methods of a national, multicenter, randomized and controlled trial to assess the efficacy of a physical activity program to improve health-related quality of life and reduce fatigue in women with metastatic breast cancer: ABLE02 trial.
    BMC Cancer. 2020;20:622.
    PubMed     Abstract available

  194. RUHNAU J, Parczyk J, Danker K, Eickholt B, et al
    Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism.
    BMC Cancer. 2020;20:617.
    PubMed     Abstract available

  195. MEZEI T, Hajdu M, Czigleczki G, Lotz G, et al
    Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review.
    BMC Cancer. 2020;20:615.
    PubMed     Abstract available

    June 2020
  196. WANG J, Cai Y, Yu F, Ping Z, et al
    Body mass index increases the lymph node metastasis risk of breast cancer: a dose-response meta-analysis with 52904 subjects from 20 cohort studies.
    BMC Cancer. 2020;20:601.
    PubMed     Abstract available

  197. TORGBENU E, Luckett T, Buhagiar MA, Chang S, et al
    Prevalence and incidence of cancer related lymphedema in low and middle-income countries: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:604.
    PubMed     Abstract available

  198. SIZEMORE G, McLaughlin S, Newman M, Brundage K, et al
    Opening large-conductance potassium channels selectively induced cell death of triple-negative breast cancer.
    BMC Cancer. 2020;20:595.
    PubMed     Abstract available

  199. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    Prediction of lymph node metastasis by tumor-infiltrating lymphocytes in T1 breast cancer.
    BMC Cancer. 2020;20:598.
    PubMed     Abstract available

  200. SONG Y, Zhao B, Xu Y, Ren X, et al
    Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer.
    BMC Cancer. 2020;20:584.
    PubMed     Abstract available

  201. FENG Q, Hu Q, Liu Y, Yang T, et al
    Diagnosis of triple negative breast cancer based on radiomics signatures extracted from preoperative contrast-enhanced chest computed tomography.
    BMC Cancer. 2020;20:579.
    PubMed     Abstract available

  202. KNAUL FM, Doubova SV, Gonzalez Robledo MC, Durstine A, et al
    Self-identity, lived experiences, and challenges of breast, cervical, and prostate cancer survivorship in Mexico: a qualitative study.
    BMC Cancer. 2020;20:577.
    PubMed     Abstract available

  203. PU Q, Lv YR, Dong K, Geng WW, et al
    Tumor suppressor OTUD3 induces growth inhibition and apoptosis by directly deubiquitinating and stabilizing p53 in invasive breast carcinoma cells.
    BMC Cancer. 2020;20:583.
    PubMed     Abstract available

  204. ZHANG Y, Yu C
    Prognostic characterization of OAS1/OAS2/OAS3/OASL in breast cancer.
    BMC Cancer. 2020;20:575.
    PubMed     Abstract available

  205. FRENCH DP, Astley S, Brentnall AR, Cuzick J, et al
    What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420).
    BMC Cancer. 2020;20:570.
    PubMed     Abstract available

  206. REPO H, Loyttyniemi E, Kurki S, Kallio L, et al
    A prognostic model based on cell-cycle control predicts outcome of breast cancer patients.
    BMC Cancer. 2020;20:558.
    PubMed     Abstract available

  207. HAGERLING C, Owyong M, Sitarama V, Wang CY, et al
    LGR5 in breast cancer and ductal carcinoma in situ: a diagnostic and prognostic biomarker and a therapeutic target.
    BMC Cancer. 2020;20:542.
    PubMed     Abstract available

  208. BOLDES T, Merenbakh-Lamin K, Journo S, Shachar E, et al
    R269C variant of ESR1: high prevalence and differential function in a subset of pancreatic cancers.
    BMC Cancer. 2020;20:531.
    PubMed     Abstract available

  209. ROSATI R, Oppat K, Huang Y, Kim S, et al
    Clinical association of progesterone receptor isoform A with breast cancer metastasis consistent with its unique mechanistic role in preclinical models.
    BMC Cancer. 2020;20:512.
    PubMed     Abstract available

  210. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ.
    BMC Cancer. 2020;20:513.
    PubMed     Abstract available

  211. SANGES F, Floris M, Cossu-Rocca P, Muroni MR, et al
    Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis.
    BMC Cancer. 2020;20:491.
    PubMed     Abstract available

  212. YANG L, Wang S, Zhang L, Sheng C, et al
    Performance of ultrasonography screening for breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:499.
    PubMed     Abstract available

  213. DEVECKA M, Duma MN, Wilkens JJ, Kampfer S, et al
    Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting.
    BMC Cancer. 2020;20:501.
    PubMed     Abstract available

    May 2020
  214. NILSSEN Y, Brustugun OT, Eriksen MT, Haug ES, et al
    Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016.
    BMC Cancer. 2020;20:488.
    PubMed     Abstract available

  215. OLSSON MOLLER U, Ryden L, Malmstrom M
    Systematic screening as a tool for individualized rehabilitation following primary breast cancer treatment: study protocol for the ReScreen randomized controlled trial.
    BMC Cancer. 2020;20:484.
    PubMed     Abstract available

  216. BARROS-OLIVEIRA MDC, Costa-Silva DR, Campos-Verdes LC, Pereira RO, et al
    CYP19A1 gene expression in the peripheral blood of Brazilian women with breast cancer relapse.
    BMC Cancer. 2020;20:480.
    PubMed     Abstract available

  217. SINGLETON DC, Dechaume AL, Murray PM, Katt WP, et al
    Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
    BMC Cancer. 2020;20:470.
    PubMed     Abstract available

  218. FARAZ M, Tellstrom A, Ardnor CE, Grankvist K, et al
    LRIG1 gene copy number analysis by ddPCR and correlations to clinical factors in breast cancer.
    BMC Cancer. 2020;20:459.
    PubMed     Abstract available

  219. LIU H, Zhan H, Sun D
    Comparison of (99m)Tc-MIBI scintigraphy, ultrasound, and mammography for the diagnosis of BI-RADS 4 category lesions.
    BMC Cancer. 2020;20:463.
    PubMed     Abstract available

  220. WOOF VG, Ruane H, French DP, Ulph F, et al
    The introduction of risk stratified screening into the NHS breast screening Programme: views from British-Pakistani women.
    BMC Cancer. 2020;20:452.
    PubMed     Abstract available

  221. LIN J, Lin KJ, Wang YF, Huang LH, et al
    Association of surgical margins with local recurrence in patients undergoing breast-conserving surgery after neoadjuvant chemotherapy.
    BMC Cancer. 2020;20:451.
    PubMed     Abstract available

  222. WESOLOWSKI R, Stiff A, Quiroga D, McQuinn C, et al
    Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
    BMC Cancer. 2020;20:445.
    PubMed     Abstract available

  223. FAHLBUSCH SS, Keil S, Epplen JT, Zanker KS, et al
    Comparison of hybrid clones derived from human breast epithelial cells and three different cancer cell lines regarding in vitro cancer stem/ initiating cell properties.
    BMC Cancer. 2020;20:446.
    PubMed     Abstract available

  224. NAUGHTON MJ, Beverly Hery CM, Janse SA, Naftalis EZ, et al
    Prevalence and correlates of job and insurance problems among young breast cancer survivors within 18 months of diagnosis.
    BMC Cancer. 2020;20:432.
    PubMed     Abstract available

    Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume.
    BMC Cancer. 2020;20:440.
    PubMed     Abstract available

  226. IWASE T, Harano K, Masuda H, Kida K, et al
    Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
    BMC Cancer. 2020;20:430.
    PubMed     Abstract available

  227. ALFARSI LH, El Ansari R, Craze ML, Masisi BK, et al
    PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer.
    BMC Cancer. 2020;20:425.
    PubMed     Abstract available

  228. OMARINI C, Piacentini F, Sperduti I, Barbolini M, et al
    Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and
    BMC Cancer. 2020;20:418.
    PubMed     Abstract available

  229. BJELIC-RADISIC V, Fitzal F, Knauer M, Steger G, et al
    Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial.
    BMC Cancer. 2020;20:392.
    PubMed     Abstract available

  230. VAN DER MERWE NC, Oosthuizen J, Theron M, Chong G, et al
    The contribution of large genomic rearrangements in BRCA1 and BRCA2 to South African familial breast cancer.
    BMC Cancer. 2020;20:391.
    PubMed     Abstract available

  231. ADAMS EJ, Asad S, Reinbolt R, Collier KA, et al
    Metastatic breast cancer patient perceptions of somatic tumor genomic testing.
    BMC Cancer. 2020;20:389.
    PubMed     Abstract available

  232. EGELAND NG, Jonsdottir K, Aure MR, Sahlberg K, et al
    MiR-18a and miR-18b are expressed in the stroma of oestrogen receptor alpha negative breast cancers.
    BMC Cancer. 2020;20:377.
    PubMed     Abstract available

  233. YOON SH, Kim HS, Kim RN, Jung SY, et al
    NAD(P)-dependent steroid dehydrogenase-like is involved in breast cancer cell growth and metastasis.
    BMC Cancer. 2020;20:375.
    PubMed     Abstract available

  234. KIM SH, Choe YH, Han AR, Yeon GJ, et al
    Design of a randomized controlled trial of a partnership-based, needs-tailored self-management support intervention for post-treatment breast cancer survivors.
    BMC Cancer. 2020;20:367.
    PubMed     Abstract available

  235. PARK JH, Lee DH, Kim SI, Kim NK, et al
    Moderate to vigorous physical activity participation associated with better quality of life among breast and colorectal cancer survivors in Korea.
    BMC Cancer. 2020;20:365.
    PubMed     Abstract available

    April 2020
  236. NYHOF BB, Wright FC, Look Hong NJ, Groot G, et al
    Identifying opportunities to support patient-centred care for ductal carcinoma in situ: qualitative interviews with clinicians.
    BMC Cancer. 2020;20:364.
    PubMed     Abstract available

  237. BLOOM MJ, Jarrett AM, Triplett TA, Syed AK, et al
    Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer.
    BMC Cancer. 2020;20:359.
    PubMed     Abstract available

  238. MCCARTHY AM, Kumar NP, He W, Regan S, et al
    Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
    BMC Cancer. 2020;20:347.
    PubMed     Abstract available

  239. THERKILDSEN C, Rasmussen M, Smith-Hansen L, Kallemose T, et al
    Broadening risk profile in familial colorectal cancer type X; increased risk for five cancer types in the national Danish cohort.
    BMC Cancer. 2020;20:345.
    PubMed     Abstract available

  240. MERY B, Fouilloux A, Rowinski E, Catella-Chatron J, et al
    Cardiovascular disease events within 5 years after a diagnosis of breast cancer.
    BMC Cancer. 2020;20:337.
    PubMed     Abstract available

  241. RAITER A, Lipovetzki J, Lubin I, Yerushalmi R, et al
    GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment.
    BMC Cancer. 2020;20:333.
    PubMed     Abstract available

  242. TANABE Y, Shiraishi S, Hashimoto K, Ikeda K, et al
    Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
    BMC Cancer. 2020;20:325.
    PubMed     Abstract available

  243. TRILLA-FUERTES L, Gamez-Pozo A, Lopez-Camacho E, Prado-Vazquez G, et al
    Computational models applied to metabolomics data hints at the relevance of glutamine metabolism in breast cancer.
    BMC Cancer. 2020;20:307.
    PubMed     Abstract available

  244. DECKER T, Soling U, Hahn A, Maintz C, et al
    Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positiv
    BMC Cancer. 2020;20:286.
    PubMed     Abstract available

  245. LIU Z, Li R, Liang K, Chen J, et al
    Value of digital mammography in predicting lymphovascular invasion of breast cancer.
    BMC Cancer. 2020;20:274.
    PubMed     Abstract available

    March 2020
  246. VAHIDI Y, Bagheri M, Ghaderi A, Faghih Z, et al
    CD8-positive memory T cells in tumor-draining lymph nodes of patients with breast cancer.
    BMC Cancer. 2020;20:257.
    PubMed     Abstract available

  247. WATANABE K, Katayama K, Yoshioka T, Narimatsu H, et al
    Impact of individual background on the unmet needs of cancer survivors and caregivers - a mixed-methods analysis.
    BMC Cancer. 2020;20:263.
    PubMed     Abstract available

  248. YANG F, Huang X, Sun C, Li J, et al
    Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population.
    BMC Cancer. 2020;20:255.
    PubMed     Abstract available

  249. RAINEY L, van der Waal D, Jervaeus A, Donnelly LS, et al
    European women's perceptions of the implementation and organisation of risk-based breast cancer screening and prevention: a qualitative study.
    BMC Cancer. 2020;20:247.
    PubMed     Abstract available

  250. HAN BY, Li XG, Zhao HY, Hu X, et al
    Clinical features and survival of pregnancy-associated breast cancer: a retrospective study of 203 cases in China.
    BMC Cancer. 2020;20:244.
    PubMed     Abstract available

  251. CAPUTO R, Cazzaniga ME, Sbrana A, Torrisi R, et al
    Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
    BMC Cancer. 2020;20:232.
    PubMed     Abstract available

  252. DING N, Huang J, Li N, Yuan J, et al
    Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy.
    BMC Cancer. 2020;20:235.
    PubMed     Abstract available

  253. FLORIS M, Sanna D, Castiglia P, Putzu C, et al
    MTHFR, XRCC1 and OGG1 genetic polymorphisms in breast cancer: a case-control study in a population from North Sardinia.
    BMC Cancer. 2020;20:234.
    PubMed     Abstract available

  254. SAN MIGUEL Y, Gomez SL, Murphy JD, Schwab RB, et al
    Age-related differences in breast cancer mortality according to race/ethnicity, insurance, and socioeconomic status.
    BMC Cancer. 2020;20:228.
    PubMed     Abstract available

  255. MOSS C, Haire A, Cahill F, Enting D, et al
    Guy's cancer cohort - real world evidence for cancer pathways.
    BMC Cancer. 2020;20:187.
    PubMed     Abstract available

  256. MEALEY NE, O'Sullivan DE, Pader J, Ruan Y, et al
    Mutational landscape differences between young-onset and older-onset breast cancer patients.
    BMC Cancer. 2020;20:212.
    PubMed     Abstract available

  257. PRZYBYTKOWSKI E, Davis T, Hosny A, Eismann J, et al
    An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    BMC Cancer. 2020;20:197.
    PubMed     Abstract available

  258. GAO G, Wang Z, Qu X, Zhang Z, et al
    Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2020;20:179.
    PubMed     Abstract available

  259. SUN Z, Lan X, Xu S, Li S, et al
    Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis.
    BMC Cancer. 2020;20:180.
    PubMed     Abstract available

  260. KHIL L, Heidrich J, Wellmann I, Kaab-Sanyal V, et al
    Incidence of advanced-stage breast cancer in regular participants of a mammography screening program: a prospective register-based study.
    BMC Cancer. 2020;20:174.
    PubMed     Abstract available

  261. ZHANG XM, Dou QL, Zeng Y, Yang Y, et al
    Sarcopenia as a predictor of mortality in women with breast cancer: a meta-analysis and systematic review.
    BMC Cancer. 2020;20:172.
    PubMed     Abstract available

    February 2020
  262. OBA T, Maeno K, Takekoshi D, Ono M, et al
    Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with breast cancer.
    BMC Cancer. 2020;20:160.
    PubMed     Abstract available

  263. LI L, Zhang H, Wang L, Xie C, et al
    A retrospective analysis on metastatic rate of the internal mammary lymph node and its clinical significance in adjuvant radiotherapy of breast cancer patients.
    BMC Cancer. 2020;20:153.
    PubMed     Abstract available

  264. PESSOA-PEREIRA D, Evangelista AF, Causin RL, da Costa Vieira RA, et al
    miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
    BMC Cancer. 2020;20:143.
    PubMed     Abstract available

  265. KALECKY K, Modisette R, Pena S, Cho YR, et al
    Integrative analysis of breast cancer profiles in TCGA by TNBC subgrouping reveals novel microRNA-specific clusters, including miR-17-92a, distinguishing basal-like 1 and basal-like 2 TNBC subtypes.
    BMC Cancer. 2020;20:141.
    PubMed     Abstract available

  266. HU G, Hu G, Zhang C, Lin X, et al
    Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
    BMC Cancer. 2020;20:136.
    PubMed     Abstract available

  267. EE C, Cave AE, Naidoo D, Bilinski K, et al
    Weight before and after a diagnosis of breast cancer or ductal carcinoma in situ: a national Australian survey.
    BMC Cancer. 2020;20:113.
    PubMed     Abstract available

  268. DETTOGNI RS, Stur E, Laus AC, da Costa Vieira RA, et al
    Potential biomarkers of ductal carcinoma in situ progression.
    BMC Cancer. 2020;20:119.
    PubMed     Abstract available

  269. EPPENBERGER-CASTORI S, Klingbiel D, Ruhstaller T, Dietrich D, et al
    Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.
    BMC Cancer. 2020;20:114.
    PubMed     Abstract available

  270. ZHOU J, Lu J, Gao C, Zeng J, et al
    Predicting the response to neoadjuvant chemotherapy for breast cancer: wavelet transforming radiomics in MRI.
    BMC Cancer. 2020;20:100.
    PubMed     Abstract available

  271. GINZAC A, Barres B, Chanchou M, Gadea E, et al
    A decrease in brown adipose tissue activity is associated with weight gain during chemotherapy in early breast cancer patients.
    BMC Cancer. 2020;20:96.
    PubMed     Abstract available

  272. NI-JIA-TI MY, Ai-Hai-Ti DL, Huo-Jia AS, Wu-Mai-Er PL, et al
    Development of a risk-stratification scoring system for predicting lymphovascular invasion in breast cancer.
    BMC Cancer. 2020;20:94.
    PubMed     Abstract available

    January 2020
  273. SOLIMAN H, Shah V, Srkalovic G, Mahtani R, et al
    MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial.
    BMC Cancer. 2020;20:81.
    PubMed     Abstract available

  274. BACOLOD MD, Huang J, Giardina SF, Feinberg PB, et al
    Prediction of blood-based biomarkers and subsequent design of bisulfite PCR-LDR-qPCR assay for breast cancer detection.
    BMC Cancer. 2020;20:85.
    PubMed     Abstract available

  275. MANOHARAN V, Karunanayake EH, Tennekoon KH, De Silva S, et al
    Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
    BMC Cancer. 2020;20:72.
    PubMed     Abstract available

  276. HA JH, Hong KY, Lee HB, Moon HG, et al
    Oncologic outcomes after immediate breast reconstruction following mastectomy: comparison of implant and flap using propensity score matching.
    BMC Cancer. 2020;20:78.
    PubMed     Abstract available

  277. YAMAZAKI R, Inokuchi M, Ishikawa S, Ayabe T, et al
    Ovarian hyperstimulation closely associated with resumption of follicular growth after chemotherapy during tamoxifen treatment in premenopausal women with breast cancer: a multicenter retrospective cohort study.
    BMC Cancer. 2020;20:67.
    PubMed     Abstract available

  278. NILSSON G, Kannius-Janson M
    Correction to: Forkhead Box F1 promotes breast cancer cell migration by upregulating lysyl oxidase and suppressing Smad2/3 signaling.
    BMC Cancer. 2020;20:55.
    PubMed     Abstract available

  279. TWELVES C, Cheeseman S, Sopwith W, Thompson M, et al
    Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre.
    BMC Cancer. 2020;20:53.
    PubMed     Abstract available

  280. NAWAS AF, Kanchwala M, Thomas-Jardin SE, Dahl H, et al
    IL-1-conferred gene expression pattern in ERalpha(+) BCa and AR(+) PCa cells is intrinsic to ERalpha(-) BCa and AR(-) PCa cells and promotes cell survival.
    BMC Cancer. 2020;20:46.
    PubMed     Abstract available

  281. HE J, Tsang JY, Xu X, Li J, et al
    AJCC 8th edition prognostic staging provides no better discriminatory ability in prognosis than anatomical staging in triple negative breast cancer.
    BMC Cancer. 2020;20:18.
    PubMed     Abstract available

  282. SHAHI THAKURI P, Gupta M, Singh S, Joshi R, et al
    Phytochemicals inhibit migration of triple negative breast cancer cells by targeting kinase signaling.
    BMC Cancer. 2020;20:4.
    PubMed     Abstract available

    December 2019
  283. DAGHER E, Royer V, Buchet P, Abadie J, et al
    Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    BMC Cancer. 2019;19:1267.
    PubMed     Abstract available

  284. SKARPING I, Fornvik D, Sartor H, Heide-Jorgensen U, et al
    Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer.
    BMC Cancer. 2019;19:1272.
    PubMed     Abstract available

  285. AL-EITAN LN, Rababa'h DM, Alghamdi MA, Khasawneh RH, et al
    Association between ESR1, ESR2, HER2, UGT1A4, and UGT2B7 polymorphisms and breast Cancer in Jordan: a case-control study.
    BMC Cancer. 2019;19:1257.
    PubMed     Abstract available

  286. GLASER RL, York AE, Dimitrakakis C
    Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study.
    BMC Cancer. 2019;19:1271.
    PubMed     Abstract available

  287. KIZILBOGA T, Baskale EA, Yildiz J, Akcay IM, et al
    Bag-1 stimulates Bad phosphorylation through activation of Akt and Raf kinases to mediate cell survival in breast cancer.
    BMC Cancer. 2019;19:1254.
    PubMed     Abstract available

  288. CAMACHO F, Anderson R, Kimmick G
    Investigating confounders of the association between survival and adjuvant radiation therapy after breast conserving surgery in a sample of elderly breast Cancer patients in Appalachia.
    BMC Cancer. 2019;19:1228.
    PubMed     Abstract available

  289. HOSHINA H, Takei H
    Granulocyte-colony stimulating factor-associated aortitis in a woman with advanced breast cancer: a case report and review of the literature.
    BMC Cancer. 2019;19:1217.
    PubMed     Abstract available

  290. MARCZYK M, Fu C, Lau R, Du L, et al
    The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues.
    BMC Cancer. 2019;19:1189.
    PubMed     Abstract available

  291. LENDE TH, Austdal M, Bathen TF, Varhaugvik AE, et al
    Metabolic consequences of perioperative oral carbohydrates in breast cancer patients - an explorative study.
    BMC Cancer. 2019;19:1183.
    PubMed     Abstract available

  292. HARVIE M, Pegington M, French D, Cooper G, et al
    Breast cancer risk status influences uptake, retention and efficacy of a weight loss programme amongst breast cancer screening attendees: two randomised controlled feasibility trials.
    BMC Cancer. 2019;19:1089.
    PubMed     Abstract available

  293. SUN X, Qu Q, Lao Y, Zhang M, et al
    Tumor suppressor HIC1 is synergistically compromised by cancer-associated fibroblasts and tumor cells through the IL-6/pSTAT3 axis in breast cancer.
    BMC Cancer. 2019;19:1180.
    PubMed     Abstract available

  294. YUAN CL, Jiang XM, Yi Y, E JF, et al
    Identification of differentially expressed lncRNAs and mRNAs in luminal-B breast cancer by RNA-sequencing.
    BMC Cancer. 2019;19:1171.
    PubMed     Abstract available

  295. ALVES WEFM, Bonatelli M, Dufloth R, Kerr LM, et al
    CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy.
    BMC Cancer. 2019;19:1173.
    PubMed     Abstract available

  296. LEE CH, Hsieh JC, Wu TM, Yeh TS, et al
    Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer.
    BMC Cancer. 2019;19:1167.
    PubMed     Abstract available

    November 2019
  297. TESAURO C, Simonsen AK, Andersen MB, Petersen KW, et al
    Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
    BMC Cancer. 2019;19:1158.
    PubMed     Abstract available

  298. YAMAGISHI Y, Koiwai T, Yamasaki T, Einama T, et al
    Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer.
    BMC Cancer. 2019;19:1146.
    PubMed     Abstract available

  299. GARCIA-GARCIA T, Carmona-Bayonas A, Jimenez-Fonseca P, Jara C, et al
    Biopsychosocial and clinical characteristics in patients with resected breast and colon cancer at the beginning and end of adjuvant treatment.
    BMC Cancer. 2019;19:1143.
    PubMed     Abstract available

  300. TJENSVOLL K, Nordgard O, Skjaeveland M, Oltedal S, et al
    Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients.
    BMC Cancer. 2019;19:1131.
    PubMed     Abstract available

  301. KRAWCZYK N, Neubacher M, Meier-Stiegen F, Neubauer H, et al
    Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients.
    BMC Cancer. 2019;19:1101.
    PubMed     Abstract available

  302. WANG R, Zhu Y, Liu X, Liao X, et al
    The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer.
    BMC Cancer. 2019;19:1091.
    PubMed     Abstract available

  303. WANG C, Li X, Su S, Wang X, et al
    Factors analysis on the use of key quality indicators for narrowing the gap of quality of care of breast cancer.
    BMC Cancer. 2019;19:1099.
    PubMed     Abstract available

  304. LU S, Yakirevich E, Wang LJ, Resnick MB, et al
    Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance.
    BMC Cancer. 2019;19:1085.
    PubMed     Abstract available

  305. LENDE TH, Austdal M, Varhaugvik AE, Skaland I, et al
    Influence of pre-operative oral carbohydrate loading vs. standard fasting on tumor proliferation and clinical outcome in breast cancer patients horizontal line a randomized trial.
    BMC Cancer. 2019;19:1076.
    PubMed     Abstract available

  306. PANDY JGP, Balolong-Garcia JC, Cruz-Ordinario MVB, Que FVF, et al
    Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.
    BMC Cancer. 2019;19:1065.
    PubMed     Abstract available

  307. LI S, Yan W, Yang X, Chen L, et al
    Less micrometastatic risk related to circulating tumor cells after endoscopic breast cancer surgery compared to open surgery.
    BMC Cancer. 2019;19:1070.
    PubMed     Abstract available

  308. JOHNSSON A, Demmelmaier I, Sjovall K, Wagner P, et al
    A single exercise session improves side-effects of chemotherapy in women with breast cancer: an observational study.
    BMC Cancer. 2019;19:1073.
    PubMed     Abstract available

  309. SUROV A, Chang YW, Li L, Martincich L, et al
    Apparent diffusion coefficient cannot predict molecular subtype and lymph node metastases in invasive breast cancer: a multicenter analysis.
    BMC Cancer. 2019;19:1043.
    PubMed     Abstract available

  310. ZHU C, Menyhart O, Gyorffy B, He X, et al
    The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy.
    BMC Cancer. 2019;19:1046.
    PubMed     Abstract available

  311. DE AMICIS F, Chiodo C, Morelli C, Casaburi I, et al
    AIB1 sequestration by androgen receptor inhibits estrogen-dependent cyclin D1 expression in breast cancer cells.
    BMC Cancer. 2019;19:1038.
    PubMed     Abstract available

  312. HILL DP, Harper A, Malcolm J, McAndrews MS, et al
    Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance.
    BMC Cancer. 2019;19:1039.
    PubMed     Abstract available

  313. BAZAN F, Dobi E, Royer B, Curtit E, et al
    Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer.
    BMC Cancer. 2019;19:1029.
    PubMed     Abstract available

  314. BOLANDGHAMAT POUR Z, Nourbakhsh M, Mousavizadeh K, Madjd Z, et al
    Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin.
    BMC Cancer. 2019;19:1027.
    PubMed     Abstract available

  315. ZHAO CL, Singh K, Brodsky AS, Lu S, et al
    Stromal ColXalpha1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer.
    BMC Cancer. 2019;19:1036.
    PubMed     Abstract available

    October 2019
  316. HANAMURA T, Ohno K, Hokibara S, Murasawa H, et al
    Clinical significance of serum PSA in breast cancer patients.
    BMC Cancer. 2019;19:1021.
    PubMed     Abstract available

  317. GOOSSENS M, De Brabander I, De Greve J, Van Ongeval C, et al
    Flemish breast cancer screening programme: 15 years of key performance indicators (2002-2016).
    BMC Cancer. 2019;19:1012.
    PubMed     Abstract available

  318. ZHANG W, Yang S, Liu J, Bao L, et al
    Screening antiproliferative drug for breast cancer from bisbenzylisoquinoline alkaloid tetrandrine and fangchinoline derivatives by targeting BLM helicase.
    BMC Cancer. 2019;19:1009.
    PubMed     Abstract available

  319. BARTON M, Santucci-Pereira J, Vaccaro OG, Nguyen T, et al
    BC200 overexpression contributes to luminal and triple negative breast cancer pathogenesis.
    BMC Cancer. 2019;19:994.
    PubMed     Abstract available

  320. SUAMI H, Heydon-White A, Mackie H, Czerniec S, et al
    A new indocyanine green fluorescence lymphography protocol for identification of the lymphatic drainage pathway for patients with breast cancer-related lymphoedema.
    BMC Cancer. 2019;19:985.
    PubMed     Abstract available

  321. PU T, Shui R, Shi J, Liang Z, et al
    External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China.
    BMC Cancer. 2019;19:978.
    PubMed     Abstract available

  322. CHEN S, Liang Y, Feng Z, Wang M, et al
    Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:973.
    PubMed     Abstract available

  323. IWASA T, Tsurutani J, Watanabe S, Kato R, et al
    Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
    BMC Cancer. 2019;19:962.
    PubMed     Abstract available

  324. ZHANG JJ, Zhang WC, An CX, Li XM, et al
    Comparative research on (99m)Tc-Rituximab and (99m)Tc-sulfur colloid in sentinel lymph node imaging of breast cancer.
    BMC Cancer. 2019;19:956.
    PubMed     Abstract available

  325. SUROV A, Meyer HJ, Wienke A
    Can apparent diffusion coefficient (ADC) distinguish breast cancer from benign breast findings? A meta-analysis based on 13 847 lesions.
    BMC Cancer. 2019;19:955.
    PubMed     Abstract available

  326. ZHOU Y, Li Y, Mao F, Zhang J, et al
    Preliminary study of contrast-enhanced ultrasound in combination with blue dye vs. indocyanine green fluorescence, in combination with blue dye for sentinel lymph node biopsy in breast cancer.
    BMC Cancer. 2019;19:939.
    PubMed     Abstract available

    September 2019
  327. MCCULLOUGH LE, Collin LJ, Conway K, White AJ, et al
    Reproductive characteristics are associated with gene-specific promoter methylation status in breast cancer.
    BMC Cancer. 2019;19:926.
    PubMed     Abstract available

  328. ZHANG J, Liu Y, Zang M, Zhu S, et al
    Lentivirus-mediated CDglyTK gene-modified free flaps by intra-artery perfusion show targeted therapeutic efficacy in rat model of breast cancer.
    BMC Cancer. 2019;19:921.
    PubMed     Abstract available

  329. BORM KJ, Schonknecht C, Nestler A, Oechsner M, et al
    Outcomes of immediate oncoplastic surgery and adjuvant radiotherapy in breast cancer patients.
    BMC Cancer. 2019;19:907.
    PubMed     Abstract available

  330. DANIELS B, Kiely BE, Tang M, Tervonen H, et al
    Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003-2015).
    BMC Cancer. 2019;19:909.
    PubMed     Abstract available

  331. SCHMID S, Klingbiel D, Aebi S, Goldhirsch A, et al
    Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
    BMC Cancer. 2019;19:902.
    PubMed     Abstract available

  332. DE HAAN R, van Werkhoven E, van den Heuvel MM, Peulen HMU, et al
    Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.
    BMC Cancer. 2019;19:901.
    PubMed     Abstract available

  333. XIAO B, Chen D, Zhou Q, Hang J, et al
    Glutamate metabotropic receptor 4 (GRM4) inhibits cell proliferation, migration and invasion in breast cancer and is regulated by miR-328-3p and miR-370-3p.
    BMC Cancer. 2019;19:891.
    PubMed     Abstract available

  334. BAYARMAA B, Wu Z, Peng J, Wang Y, et al
    Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer.
    BMC Cancer. 2019;19:877.
    PubMed     Abstract available

  335. KRZYZANOWSKA MK, Julian JA, Powis M, Howell D, et al
    Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol.
    BMC Cancer. 2019;19:884.
    PubMed     Abstract available

  336. MCQUERRY JA, Jenkins DF, Yost SE, Zhang Y, et al
    Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes.
    BMC Cancer. 2019;19:881.
    PubMed     Abstract available

  337. REN ZJ, Cao DH, Zhang Q, Ren PW, et al
    First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:871.
    PubMed     Abstract available

    August 2019
  338. KIM WH, Kim HJ, Kim SH, Jung JH, et al
    Ultrasound-guided dual-localization for axillary nodes before and after neoadjuvant chemotherapy with clip and activated charcoal in breast cancer patients: a feasibility study.
    BMC Cancer. 2019;19:859.
    PubMed     Abstract available

  339. LAWRANCE S, Bui C, Mahindra V, Arcorace M, et al
    Assessing a modified-AJCC TNM staging system in the New South Wales Cancer Registry, Australia.
    BMC Cancer. 2019;19:850.
    PubMed     Abstract available

  340. YOU Q, Fang Y, Li C, Tan Y, et al
    Multiple metastases of bones and sigmoid colon after mastectomy for ductal carcinoma in situ of the breast: a case report.
    BMC Cancer. 2019;19:844.
    PubMed     Abstract available

  341. CHAE BJ, Lee J, Lee SK, Shin HJ, et al
    Unmet needs and related factors of Korean breast cancer survivors: a multicenter, cross-sectional study.
    BMC Cancer. 2019;19:839.
    PubMed     Abstract available

  342. WONDIMAGEGNEHU A, Abebe W, Abraha A, Teferra S, et al
    Depression and social support among breast cancer patients in Addis Ababa, Ethiopia.
    BMC Cancer. 2019;19:836.
    PubMed     Abstract available

  343. ZENG L, Deng X, Zhong J, Yuan L, et al
    Prognostic value of biomarkers EpCAM and alphaB-crystallin associated with lymphatic metastasis in breast cancer by iTRAQ analysis.
    BMC Cancer. 2019;19:831.
    PubMed     Abstract available

  344. WAHABI K, Perwez A, Kamarudheen S, Bhat ZI, et al
    Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients.
    BMC Cancer. 2019;19:820.
    PubMed     Abstract available

  345. NUR U, El Reda D, Hashim D, Weiderpass E, et al
    A prospective investigation of oral contraceptive use and breast cancer mortality: findings from the Swedish women's lifestyle and health cohort.
    BMC Cancer. 2019;19:807.
    PubMed     Abstract available

  346. MA H, Malone KE, McDonald JA, Marchbanks PA, et al
    Pre-diagnosis alcohol consumption and mortality risk among black women and white women with invasive breast cancer.
    BMC Cancer. 2019;19:800.
    PubMed     Abstract available

  347. SEPAHI I, Faust U, Sturm M, Bosse K, et al
    Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women.
    BMC Cancer. 2019;19:787.
    PubMed     Abstract available

  348. KIM CY, Kim N, Choung HK, In Khwarg S, et al
    Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla(R), T-DM1) administration: a case report.
    BMC Cancer. 2019;19:774.
    PubMed     Abstract available

  349. GOMES CP, Nobrega-Pereira S, Domingues-Silva B, Rebelo K, et al
    An antisense transcript mediates MALAT1 response in human breast cancer.
    BMC Cancer. 2019;19:771.
    PubMed     Abstract available

    July 2019
  350. BARRENO L, Caceres S, Alonso-Diez A, Vicente-Montana A, et al
    Vasculogenic mimicry-associated ultrastructural findings in human and canine inflammatory breast cancer cell lines.
    BMC Cancer. 2019;19:750.
    PubMed     Abstract available

  351. LATTANZIO R, Iezzi M, Sala G, Tinari N, et al
    PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes.
    BMC Cancer. 2019;19:747.
    PubMed     Abstract available

  352. KOCIK J, Pajaczek M, Kryczka T
    Worse survival in breast cancer in elderly may not be due to underutilization of medical procedures as observed upon changing healthcare system in Poland.
    BMC Cancer. 2019;19:749.
    PubMed     Abstract available

  353. WANG H, Tan Z, Hu H, Liu H, et al
    microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1.
    BMC Cancer. 2019;19:738.
    PubMed     Abstract available

  354. CARAYOL M, Ninot G, Senesse P, Bleuse JP, et al
    Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the "APAD1" randomized controlled trial.
    BMC Cancer. 2019;19:737.
    PubMed     Abstract available

  355. TIAINEN L, Korhonen EA, Leppanen VM, Luukkaala T, et al
    High baseline Tie1 level predicts poor survival in metastatic breast cancer.
    BMC Cancer. 2019;19:732.
    PubMed     Abstract available

  356. QIU Y, Wang L, Zhong X, Li L, et al
    A multiple breast cancer stem cell model to predict recurrence of T1-3, N0 breast cancer.
    BMC Cancer. 2019;19:729.
    PubMed     Abstract available

  357. ESPARZA-LOPEZ J, Alvarado-Munoz JF, Escobar-Arriaga E, Ulloa-Aguirre A, et al
    Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-kappaB pathways.
    BMC Cancer. 2019;19:728.
    PubMed     Abstract available

  358. ZAYAS-VILLANUEVA OA, Campos-Acevedo LD, Lugo-Trampe JJ, Hernandez-Barajas D, et al
    Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
    BMC Cancer. 2019;19:722.
    PubMed     Abstract available

  359. CASEY MC, Prakash A, Holian E, McGuire A, et al
    Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer.
    BMC Cancer. 2019;19:712.
    PubMed     Abstract available

  360. LAIBLE M, Hartmann K, Gurtler C, Anzeneder T, et al
    Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy.
    BMC Cancer. 2019;19:694.
    PubMed     Abstract available

  361. DANZINGER S, Tan YY, Rudas M, Kastner MT, et al
    Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
    BMC Cancer. 2019;19:695.
    PubMed     Abstract available

  362. MARKL B, Kazik M, Harbeck N, Jakubowicz E, et al
    Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer.
    BMC Cancer. 2019;19:692.
    PubMed     Abstract available

  363. LIM SM, Han Y, Kim SI, Park HS, et al
    Utilization of bioelectrical impedance analysis for detection of lymphedema in breast Cancer survivors: a prospective cross sectional study.
    BMC Cancer. 2019;19:669.
    PubMed     Abstract available

  364. MARTIN-PARDILLOS A, Valls Chiva A, Bande Vargas G, Hurtado Blanco P, et al
    The role of clonal communication and heterogeneity in breast cancer.
    BMC Cancer. 2019;19:666.
    PubMed     Abstract available

  365. MCBRIDE ML, Groome PA, Decker K, Kendell C, et al
    Adherence to quality breast cancer survivorship care in four Canadian provinces: a CanIMPACT retrospective cohort study.
    BMC Cancer. 2019;19:659.
    PubMed     Abstract available

  366. SINGLETON A, Partridge SR, Raeside R, Regimbal M, et al
    A text message intervention to support women's physical and mental health after breast cancer treatments (EMPOWER-SMS): a randomised controlled trial protocol.
    BMC Cancer. 2019;19:660.
    PubMed     Abstract available

  367. LEE K, Kang I, Mack WJ, Mortimer J, et al
    Feasibility of high intensity interval training in patients with breast Cancer undergoing anthracycline chemotherapy: a randomized pilot trial.
    BMC Cancer. 2019;19:653.
    PubMed     Abstract available

  368. ADLARD KN, Jenkins DG, Salisbury CE, Bolam KA, et al
    Peer support for the maintenance of physical activity and health in cancer survivors: the PEER trial - a study protocol of a randomised controlled trial.
    BMC Cancer. 2019;19:656.
    PubMed     Abstract available

    June 2019
  369. HANNAFON BN, Cai A, Calloway CL, Xu YF, et al
    miR-23b and miR-27b are oncogenic microRNAs in breast cancer: evidence from a CRISPR/Cas9 deletion study.
    BMC Cancer. 2019;19:642.
    PubMed     Abstract available

  370. CHEN JH, Huang WC, Bamodu OA, Chang PM, et al
    Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
    BMC Cancer. 2019;19:634.
    PubMed     Abstract available

  371. MORAN O, Eisen A, Demsky R, Blackmore K, et al
    Predictors of mammographic density among women with a strong family history of breast cancer.
    BMC Cancer. 2019;19:631.
    PubMed     Abstract available

  372. MAJID S, Ryden L, Manjer J
    Determinants for non-sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 602 consecutive patients with sentinel node metastases.
    BMC Cancer. 2019;19:626.
    PubMed     Abstract available

  373. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    Verification of the effects of calcium channel blockers on the immune microenvironment of breast cancer.
    BMC Cancer. 2019;19:615.
    PubMed     Abstract available

  374. PEREZ EA, de Haas SL, Eiermann W, Barrios CH, et al
    Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine +/- pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    BMC Cancer. 2019;19:620.
    PubMed     Abstract available

  375. WALLWIENER M, Nabieva N, Feisst M, Fehm T, et al
    Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study.
    BMC Cancer. 2019;19:611.
    PubMed     Abstract available

  376. DIHGE L, Ohlsson M, Eden P, Bendahl PO, et al
    Artificial neural network models to predict nodal status in clinically node-negative breast cancer.
    BMC Cancer. 2019;19:610.
    PubMed     Abstract available

  377. GEBREHIWOT AG, Melka DS, Kassaye YM, Gemechu T, et al
    Exploring serum and immunoglobulin G N-glycome as diagnostic biomarkers for early detection of breast cancer in Ethiopian women.
    BMC Cancer. 2019;19:588.
    PubMed     Abstract available

  378. RESENDE U, Cabello C, Ramalho SOB, Zeferino LC, et al
    Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    BMC Cancer. 2019;19:601.
    PubMed     Abstract available

  379. WANG C, Xu C, Niu R, Hu G, et al
    MiR-890 inhibits proliferation and invasion and induces apoptosis in triple-negative breast cancer cells by targeting CD147.
    BMC Cancer. 2019;19:577.
    PubMed     Abstract available

  380. KUMLER I, Balslev E, Stenvang J, Brunner N, et al
    Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene.
    BMC Cancer. 2019;19:573.
    PubMed     Abstract available

  381. SCHWARTZBERG L, McIntyre K, Wilks S, Puhalla S, et al
    Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
    BMC Cancer. 2019;19:578.
    PubMed     Abstract available

  382. TORDJMAN J, Majumder M, Amiri M, Hasan A, et al
    Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells.
    BMC Cancer. 2019;19:561.
    PubMed     Abstract available

  383. KAREDATH T, Ahmed I, Al Ameri W, Al-Dasim FM, et al
    Silencing of ANKRD12 circRNA induces molecular and functional changes associated with invasive phenotypes.
    BMC Cancer. 2019;19:565.
    PubMed     Abstract available

  384. VRINTEN C, Gallagher A, Waller J, Marlow LAV, et al
    Cancer stigma and cancer screening attendance: a population based survey in England.
    BMC Cancer. 2019;19:566.
    PubMed     Abstract available

  385. ZHANG J, Li K, Zhang Y, Lu R, et al
    Deletion of sorting nexin 27 suppresses proliferation in highly aggressive breast cancer MDA-MB-231 cells in vitro and in vivo.
    BMC Cancer. 2019;19:555.
    PubMed     Abstract available

  386. LALL K, Lepamets M, Palover M, Esko T, et al
    Polygenic prediction of breast cancer: comparison of genetic predictors and implications for risk stratification.
    BMC Cancer. 2019;19:557.
    PubMed     Abstract available

  387. BUSTAMANTE EDUARDO M, Popovici V, Imboden S, Aebi S, et al
    Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
    BMC Cancer. 2019;19:549.
    PubMed     Abstract available

  388. CAO WM, Zheng YB, Gao Y, Ding XW, et al
    Comprehensive mutation detection of BRCA1/2 genes reveals large genomic rearrangements contribute to hereditary breast and ovarian cancer in Chinese women.
    BMC Cancer. 2019;19:551.
    PubMed     Abstract available

  389. YANG Y, Wang Y, Deng H, Tan C, et al
    Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer.
    BMC Cancer. 2019;19:541.
    PubMed     Abstract available

  390. CHANG VC, Cotterchio M, Khoo E
    Iron intake, body iron status, and risk of breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:543.
    PubMed     Abstract available

  391. TSAOUSIS GN, Papadopoulou E, Apessos A, Agiannitopoulos K, et al
    Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
    BMC Cancer. 2019;19:535.
    PubMed     Abstract available

    May 2019
  392. PEREZ EA, de Haas SL, Eiermann W, Barrios CH, et al
    Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine +/- pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    BMC Cancer. 2019;19:517.
    PubMed     Abstract available

  393. HOLLECZEK B, Stegmaier C, Radosa JC, Solomayer EF, et al
    Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis - results from a registry-based study from Germany.
    BMC Cancer. 2019;19:520.
    PubMed     Abstract available

  394. KIKUCHI-KOIKE R, Nagasaka K, Tsuda H, Ishii Y, et al
    Array comparative genomic hybridization analysis discloses chromosome copy number alterations as indicators of patient outcome in lymph node-negative breast cancer.
    BMC Cancer. 2019;19:521.
    PubMed     Abstract available

  395. PLAZA-DIAZ J, Alvarez-Mercado AI, Ruiz-Marin CM, Reina-Perez I, et al
    Association of breast and gut microbiota dysbiosis and the risk of breast cancer: a case-control clinical study.
    BMC Cancer. 2019;19:495.
    PubMed     Abstract available

  396. RUTKOVSKY AC, Yeh ES, Guest ST, Findlay VJ, et al
    Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer.
    BMC Cancer. 2019;19:491.
    PubMed     Abstract available

  397. OLSSON MOLLER U, Beck I, Ryden L, Malmstrom M, et al
    A comprehensive approach to rehabilitation interventions following breast cancer treatment - a systematic review of systematic reviews.
    BMC Cancer. 2019;19:472.
    PubMed     Abstract available

  398. PEISL S, Zimmermann S, Camey B, Betticher D, et al
    Comparison between opportunistic and organised breast cancer mammography screening in the Swiss canton of Fribourg.
    BMC Cancer. 2019;19:469.
    PubMed     Abstract available

  399. YANG X, Zhang K, Zhang C, Peng R, et al
    Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
    BMC Cancer. 2019;19:465.
    PubMed     Abstract available

  400. BURM R, Thewes B, Rodwell L, Kievit W, et al
    Long-term efficacy and cost-effectiveness of blended cognitive behavior therapy for high fear of recurrence in breast, prostate and colorectal Cancer survivors: follow-up of the SWORD randomized controlled trial.
    BMC Cancer. 2019;19:462.
    PubMed     Abstract available

  401. WANG K, Wang G, Huang S, Luo A, et al
    Association between TIMP-2 gene polymorphism and breast cancer in Han Chinese women.
    BMC Cancer. 2019;19:446.
    PubMed     Abstract available

  402. ZHENG A, Zhang L, Song X, Wang Y, et al
    Clinical implications of a novel prognostic factor AIFM3 in breast cancer patients.
    BMC Cancer. 2019;19:451.
    PubMed     Abstract available

  403. YI Z, Ma F, Liu B, Guan X, et al
    Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
    BMC Cancer. 2019;19:442.
    PubMed     Abstract available

  404. MCANENA P, Tanriverdi K, Curran C, Gilligan K, et al
    Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.
    BMC Cancer. 2019;19:436.
    PubMed     Abstract available

  405. VALE DB, Filho CC, Shinzato JY, Spreafico FS, et al
    Downstaging in opportunistic breast cancer screening in Brazil: a temporal trend analysis.
    BMC Cancer. 2019;19:432.
    PubMed     Abstract available

  406. ARAS S, Maroun MC, Song Y, Bandyopadhyay S, et al
    Mitochondrial autoimmunity and MNRR1 in breast carcinogenesis.
    BMC Cancer. 2019;19:411.
    PubMed     Abstract available

    April 2019
  407. ZAKRZEWSKI F, Gieldon L, Rump A, Seifert M, et al
    Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
    BMC Cancer. 2019;19:396.
    PubMed     Abstract available

  408. DERESSA BT, Cihoric N, Badra EV, Tsikkinis A, et al
    Breast cancer care in northern Ethiopia - cross-sectional analysis.
    BMC Cancer. 2019;19:393.
    PubMed     Abstract available

  409. LEE J, Lee EH, Park HY, Kim WW, et al
    Efficacy of an RNA-based multigene assay with core needle biopsy samples for risk evaluation in hormone-positive early breast cancer.
    BMC Cancer. 2019;19:388.
    PubMed     Abstract available

  410. ZHAO Y, Luo H, Zhang X, Bianba T, et al
    Clinicopathological characteristics and health care for Tibetan women with breast cancer: a cross-sectional survey.
    BMC Cancer. 2019;19:380.
    PubMed     Abstract available

  411. LU L, Huang H, Zhou J, Ma W, et al
    BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer.
    BMC Cancer. 2019;19:387.
    PubMed     Abstract available

  412. SALERNO EA, Rowland K, Kramer AF, McAuley E, et al
    Acute aerobic exercise effects on cognitive function in breast cancer survivors: a randomized crossover trial.
    BMC Cancer. 2019;19:371.
    PubMed     Abstract available

  413. CHAO X, Chen K, Zeng J, Bi Z, et al
    Adjuvant radiotherapy and chemotherapy for patients with breast phyllodes tumors: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:372.
    PubMed     Abstract available

  414. RUFFALO M, Bar-Joseph Z
    Protein interaction disruption in cancer.
    BMC Cancer. 2019;19:370.
    PubMed     Abstract available

  415. BRUNORO GVF, Carvalho PC, Barbosa VC, Pagnoncelli D, et al
    Differential proteomic comparison of breast cancer secretome using a quantitative paired analysis workflow.
    BMC Cancer. 2019;19:365.
    PubMed     Abstract available

  416. MCCLEMENTS L, Annett S, Yakkundi A, O'Rourke M, et al
    FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
    BMC Cancer. 2019;19:351.
    PubMed     Abstract available

  417. GASS J, Mitchell S, Hanna M
    How do breast cancer surgery scars impact survivorship? Findings from a nationwide survey in the United States.
    BMC Cancer. 2019;19:342.
    PubMed     Abstract available

  418. ZHANG W, Jin ZQ, Baikpour M, Li JM, et al
    Clinical application of ultrasound-guided percutaneous microwave ablation for benign breast lesions: a prospective study.
    BMC Cancer. 2019;19:345.
    PubMed     Abstract available

  419. HEUSER C, Diekmann A, Kowalski C, Enders A, et al
    Health literacy and patient participation in multidisciplinary tumor conferences in breast cancer care: a multilevel modeling approach.
    BMC Cancer. 2019;19:330.
    PubMed     Abstract available

  420. SAVCI-HEIJINK CD, Halfwerk H, Koster J, Horlings HM, et al
    A specific gene expression signature for visceral organ metastasis in breast cancer.
    BMC Cancer. 2019;19:333.
    PubMed     Abstract available

  421. WU L, Wu D, Ning J, Liu W, et al
    Changes of N6-methyladenosine modulators promote breast cancer progression.
    BMC Cancer. 2019;19:326.
    PubMed     Abstract available

  422. CAMPOY EM, Branham MT, Mayorga LS, Roque M, et al
    Intratumor heterogeneity index of breast carcinomas based on DNA methylation profiles.
    BMC Cancer. 2019;19:328.
    PubMed     Abstract available

  423. SHAHI RB, De Brakeleer S, Caljon B, Pauwels I, et al
    Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families.
    BMC Cancer. 2019;19:313.
    PubMed     Abstract available

  424. FERRARO DA, Patella F, Zanivan S, Donato C, et al
    Endothelial cell-derived nidogen-1 inhibits migration of SK-BR-3 breast cancer cells.
    BMC Cancer. 2019;19:312.
    PubMed     Abstract available

  425. RAIHAN J, Ahmad U, Yong YK, Eshak Z, et al
    Regression of solid breast tumours in mice by Newcastle disease virus is associated with production of apoptosis related-cytokines.
    BMC Cancer. 2019;19:315.
    PubMed     Abstract available

  426. KLEIN J, Tran W, Watkins E, Vesprini D, et al
    Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis.
    BMC Cancer. 2019;19:306.
    PubMed     Abstract available

  427. CAMPBELL EJ, Dachs GU, Morrin HR, Davey VC, et al
    Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels.
    BMC Cancer. 2019;19:307.
    PubMed     Abstract available

  428. MULLAN PB, Bingham V, Haddock P, Irwin GW, et al
    NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer.
    BMC Cancer. 2019;19:236.
    PubMed     Abstract available

    March 2019
  429. CAPERCHIONE CM, Sabiston CM, Stolp S, Bottorff JL, et al
    A preliminary trial examining a 'real world' approach for increasing physical activity among breast cancer survivors: findings from project MOVE.
    BMC Cancer. 2019;19:272.
    PubMed     Abstract available

  430. MENDIETA I, Nunez-Anita RE, Nava-Villalba M, Zambrano-Estrada X, et al
    Molecular iodine exerts antineoplastic effects by diminishing proliferation and invasive potential and activating the immune response in mammary cancer xenografts.
    BMC Cancer. 2019;19:261.
    PubMed     Abstract available

  431. ABDULRASHID K, AlHussaini N, Ahmed W, Thalib L, et al
    Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis.
    BMC Cancer. 2019;19:256.
    PubMed     Abstract available

  432. KIM MH, Kim DW, Park S, Kim JH, et al
    Single dose of dexamethasone is not associated with postoperative recurrence and mortality in breast cancer patients: a propensity-matched cohort study.
    BMC Cancer. 2019;19:251.
    PubMed     Abstract available

  433. ATTULURI AK, Serkad CPV, Gunda A, Ramkumar C, et al
    Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor positive breast cancer patients.
    BMC Cancer. 2019;19:249.
    PubMed     Abstract available

  434. SMELAND HY, Lu N, Karlsen TV, Salvesen G, et al
    Stromal integrin alpha11-deficiency reduces interstitial fluid pressure and perturbs collagen structure in triple-negative breast xenograft tumors.
    BMC Cancer. 2019;19:234.
    PubMed     Abstract available

  435. YADAV S, Hartkop S, Cardenas PY, Ladkany R, et al
    Utilization of a breast cancer risk assessment tool by internal medicine residents in a primary care clinic: impact of an educational program.
    BMC Cancer. 2019;19:228.
    PubMed     Abstract available

  436. PHUNG MT, Tin Tin S, Elwood JM
    Prognostic models for breast cancer: a systematic review.
    BMC Cancer. 2019;19:230.
    PubMed     Abstract available

  437. RAMIREZ AB, Bhat R, Sahay D, De Angelis C, et al
    Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.
    BMC Cancer. 2019;19:220.
    PubMed     Abstract available

  438. DE ALMEIDA BP, Apolonio JD, Binnie A, Castelo-Branco P, et al
    Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers.
    BMC Cancer. 2019;19:219.
    PubMed     Abstract available

  439. CHAI D, Li K, Du H, Yang S, et al
    beta2-microglobulin has a different regulatory molecular mechanism between ER(+) and ER(-) breast cancer with HER2().
    BMC Cancer. 2019;19:223.
    PubMed     Abstract available

  440. CHEN Q, Liu Y, Zhu XL, Feng F, et al
    Increased NHE1 expression is targeted by specific inhibitor cariporide to sensitize resistant breast cancer cells to doxorubicin in vitro and in vivo.
    BMC Cancer. 2019;19:211.
    PubMed     Abstract available

  441. XU Y, Kong S, Cheung WY, Bouchard-Fortier A, et al
    Development and validation of case-finding algorithms for recurrence of breast cancer using routinely collected administrative data.
    BMC Cancer. 2019;19:210.
    PubMed     Abstract available

  442. KUMAR N, Zhao D, Bhaumik D, Sethi A, et al
    Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes.
    BMC Cancer. 2019;19:215.
    PubMed     Abstract available

  443. MATOSSIAN MD, Burks HE, Elliott S, Hoang VT, et al
    Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.
    BMC Cancer. 2019;19:205.
    PubMed     Abstract available

  444. KATUWAL S, Tapanainen JS, Pukkala E, Kauppila A, et al
    The effect of length of birth interval on the risk of breast cancer by subtype in grand multiparous women.
    BMC Cancer. 2019;19:199.
    PubMed     Abstract available

  445. NARANG P, Chen M, Sharma AA, Anderson KS, et al
    The neoepitope landscape of breast cancer: implications for immunotherapy.
    BMC Cancer. 2019;19:200.
    PubMed     Abstract available

    February 2019
  446. DE LARA S, Nyqvist J, Werner Ronnerman E, Helou K, et al
    The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
    BMC Cancer. 2019;19:187.
    PubMed     Abstract available

  447. LIU H, Wang SH, Chen SC, Chen CY, et al
    Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells.
    BMC Cancer. 2019;19:176.
    PubMed     Abstract available

  448. LIU H, Chang X, Shang H, Li F, et al
    Diffuse cavernous hemangioma of the skull misdiagnosed as skull metastasis in breast cancer patient: one case report and literature review.
    BMC Cancer. 2019;19:172.
    PubMed     Abstract available

  449. RUIZ A, Sebagh M, Saffroy R, Allard MA, et al
    Chronological occurrence of PI3KCA mutations in breast cancer liver metastases after repeat partial liver resection.
    BMC Cancer. 2019;19:169.
    PubMed     Abstract available

  450. WOODHEAD C, Cunningham R, Ashworth M, Barley E, et al
    Correction to: Cervical and breast cancer screening uptake among women with serious mental illness: a data linkage study.
    BMC Cancer. 2019;19:152.
    PubMed     Abstract available

  451. KHAN OF, Cusano E, Raissouni S, Pabia M, et al
    Immediate-term cognitive impairment following intravenous (IV) chemotherapy: a prospective pre-post design study.
    BMC Cancer. 2019;19:150.
    PubMed     Abstract available

  452. PETITJEAN A, Smith-Palmer J, Valentine W, Tehard B, et al
    Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.
    BMC Cancer. 2019;19:140.
    PubMed     Abstract available

  453. AL-SALAM S, Sudhadevi M, Awwad A, Al Bashir M, et al
    Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy.
    BMC Cancer. 2019;19:135.
    PubMed     Abstract available

  454. WANG L, Liu L, Lou Z, Ding L, et al
    Risk prediction for breast Cancer in Han Chinese women based on a cause-specific Hazard model.
    BMC Cancer. 2019;19:128.
    PubMed     Abstract available

  455. OGITA M, Sekiguchi K, Akahane K, Ito R, et al
    Damage to sebaceous gland and the efficacy of moisturizer after whole breast radiotherapy: a randomized controlled trial.
    BMC Cancer. 2019;19:125.
    PubMed     Abstract available

  456. KAHAN Z, Grecea D, Smakal M, Tjulandin S, et al
    Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
    BMC Cancer. 2019;19:122.
    PubMed     Abstract available

  457. KONIG L, Mairinger FD, Hoffmann O, Bittner AK, et al
    Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer.
    BMC Cancer. 2019;19:120.
    PubMed     Abstract available

  458. GALLARDO-ALVARADO LN, Tusie-Luna MT, Tussie-Luna MI, Diaz-Chavez J, et al
    Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
    BMC Cancer. 2019;19:118.
    PubMed     Abstract available

    January 2019
  459. DARLIX A, Hirtz C, Thezenas S, Maceski A, et al
    The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.
    BMC Cancer. 2019;19:110.
    PubMed     Abstract available

  460. SCHAFFAR R, Belot A, Rachet B, Woods L, et al
    On the use of flexible excess hazard regression models for describing long-term breast cancer survival: a case-study using population-based cancer registry data.
    BMC Cancer. 2019;19:107.
    PubMed     Abstract available

  461. MUMIN NH, Drobnitzky N, Patel A, Lourenco LM, et al
    Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer.
    BMC Cancer. 2019;19:102.
    PubMed     Abstract available

  462. SUAREZ-KELLY LP, Pasley WH, Clayton EJ, Povoski SP, et al
    Effect of topical microporous polysaccharide hemospheres on the duration and amount of fluid drainage following mastectomy: a prospective randomized clinical trial.
    BMC Cancer. 2019;19:99.
    PubMed     Abstract available

  463. ZHAO ZM, Yost SE, Hutchinson KE, Li SM, et al
    CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
    BMC Cancer. 2019;19:96.
    PubMed     Abstract available

  464. KOTSAKIS A, Ardavanis A, Koumakis G, Samantas E, et al
    Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
    BMC Cancer. 2019;19:88.
    PubMed     Abstract available

  465. EBNER F, Wockel A, Schwentner L, Blettner M, et al
    Does the number of removed axillary lymphnodes in high risk breast cancer patients influence the survival?
    BMC Cancer. 2019;19:90.
    PubMed     Abstract available

  466. MEERSON A, Eliraz Y, Yehuda H, Knight B, et al
    Obesity impacts the regulation of miR-10b and its targets in primary breast tumors.
    BMC Cancer. 2019;19:86.
    PubMed     Abstract available

  467. KIM HK, Lee SH, Kim YJ, Park SE, et al
    Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
    BMC Cancer. 2019;19:84.
    PubMed     Abstract available

  468. MIAH S, Bagu E, Goel R, Ogunbolude Y, et al
    Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.
    BMC Cancer. 2019;19:78.
    PubMed     Abstract available

  469. KANOMATA N, Kurebayashi J, Koike Y, Yamaguchi R, et al
    CD1d- and PJA2-related immune microenvironment differs between invasive breast carcinomas with and without a micropapillary feature.
    BMC Cancer. 2019;19:76.
    PubMed     Abstract available

  470. JEVRIC M, Matic IZ, Krivokuca A, Dordic Crnogorac M, et al
    Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
    BMC Cancer. 2019;19:71.
    PubMed     Abstract available

  471. KIRKHAM AA, Ian Paterson D, Prado CM, Mackey JR, et al
    Correction to: Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer.
    BMC Cancer. 2019;19:75.
    PubMed     Abstract available

  472. KHODABANDEHLOU N, Mostafaei S, Etemadi A, Ghasemi A, et al
    Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins.
    BMC Cancer. 2019;19:61.
    PubMed     Abstract available

  473. BORGQUIST S, Broberg P, Tojjar J, Olsson H, et al
    Statin use and breast cancer survival - a Swedish nationwide study.
    BMC Cancer. 2019;19:54.
    PubMed     Abstract available

  474. HOUVENAEGHEL G, Lambaudie E, Classe JM, Mazouni C, et al
    Lymph node positivity in different early breast carcinoma phenotypes: a predictive model.
    BMC Cancer. 2019;19:45.
    PubMed     Abstract available

  475. LOFTERS AK, McBride ML, Li D, Whitehead M, et al
    Disparities in breast cancer diagnosis for immigrant women in Ontario and BC: results from the CanIMPACT study.
    BMC Cancer. 2019;19:42.
    PubMed     Abstract available

  476. FRAMARINO-DEI-MALATESTA M, Chiarito A, Bianciardi F, Fiorelli M, et al
    Metastases to extraocular muscles from breast cancer: case report and up-to-date review of the literature.
    BMC Cancer. 2019;19:36.
    PubMed     Abstract available

  477. MECHERA R, Soysal SD, Piscuoglio S, Ng CKY, et al
    Expression of RET is associated with Oestrogen receptor expression but lacks prognostic significance in breast cancer.
    BMC Cancer. 2019;19:41.
    PubMed     Abstract available

  478. SUN J, Wang X, Wang C
    Invasive cystic hypersecretory carcinoma of the breast: a rare variant of breast cancer: a case report and review of the literature.
    BMC Cancer. 2019;19:31.
    PubMed     Abstract available

  479. ZHU L, Chen K
    Clinicopathological features, treatment patterns, and prognosis of squamous cell carcinoma of the breast: an NCDB analysis.
    BMC Cancer. 2019;19:26.
    PubMed     Abstract available

  480. MASELLI-SCHOUERI JH, Affonso-Kaufman FA, de Melo Sette CV, Dos Santos Figueiredo FW, et al
    Time trend of breast cancer mortality in BRAZILIAN men: 10-year data analysis from 2005 to 2015.
    BMC Cancer. 2019;19:23.
    PubMed     Abstract available

  481. DE KRUIF JTCM, Visser M, van den Berg MMGA, Derks MJM, et al
    A longitudinal mixed methods study on changes in body weight, body composition, and lifestyle in breast cancer patients during chemotherapy and in a comparison group of women without cancer: study protocol.
    BMC Cancer. 2019;19:7.
    PubMed     Abstract available

  482. COTRIM DP, Ribeiro ARG, Paixao D, de Queiroz Soares DC, et al
    Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
    BMC Cancer. 2019;19:4.
    PubMed     Abstract available

    December 2018
  483. HAMDI Y, Ben Rekaya M, Jingxuan S, Nagara M, et al
    A genome wide SNP genotyping study in the Tunisian population: specific reporting on a subset of common breast cancer risk loci.
    BMC Cancer. 2018;18:1295.
    PubMed     Abstract available

  484. ZHAO J, Hu C, Wang C, Yu W, et al
    Breast cancer primary tumor ER expression pattern predicts its expression concordance in matched synchronous lymph node metastases.
    BMC Cancer. 2018;18:1290.
    PubMed     Abstract available

  485. TAKUWA H, Tsuji W, Shintaku M, Yotsumoto F, et al
    Hormone signaling via androgen receptor affects breast cancer and prostate cancer in a male patient: A case report.
    BMC Cancer. 2018;18:1282.
    PubMed     Abstract available

  486. SSEMMANDA S, Katagirya E, Bukirwa P, Alele D, et al
    Breast diseases histologically diagnosed at a tertiary facility in Uganda (2005-2014).
    BMC Cancer. 2018;18:1285.
    PubMed     Abstract available

  487. KUEHNEMUTH B, Piseddu I, Wiedemann GM, Lauseker M, et al
    CCL1 is a major regulatory T cell attracting factor in human breast cancer.
    BMC Cancer. 2018;18:1278.
    PubMed     Abstract available

  488. SCHMID R, Wolf K, Robering JW, Strauss S, et al
    ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro.
    BMC Cancer. 2018;18:1273.
    PubMed     Abstract available

  489. HICKS DG, Buscaglia B, Goda H, McMahon L, et al
    A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study.
    BMC Cancer. 2018;18:1266.
    PubMed     Abstract available

  490. FORSARE C, Bak M, Falck AK, Grabau D, et al
    Non-linear transformations of age at diagnosis, tumor size, and number of positive lymph nodes in prediction of clinical outcome in breast cancer.
    BMC Cancer. 2018;18:1226.
    PubMed     Abstract available

  491. MOHAMMAD AS, Adkins CE, Shah N, Aljammal R, et al
    Permeability changes and effect of chemotherapy in brain adjacent to tumor in an experimental model of metastatic brain tumor from breast cancer.
    BMC Cancer. 2018;18:1225.
    PubMed     Abstract available

  492. ANNUNZIATA MA, Muzzatti B, Bomben F, Flaiban C, et al
    A contribution to the validation of the Italian version of the Body Image Scale (BIS).
    BMC Cancer. 2018;18:1222.
    PubMed     Abstract available

  493. FARIAS AJ, Wu WH, Du XL
    Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data.
    BMC Cancer. 2018;18:1214.
    PubMed     Abstract available

  494. LI TY, Chen VC, Yeh DC, Huang SL, et al
    Investigation of chemotherapy-induced brain structural alterations in breast cancer patients with generalized q-sampling MRI and graph theoretical analysis.
    BMC Cancer. 2018;18:1211.
    PubMed     Abstract available

    November 2018
  495. AL-QASSAB Y, Grassilli S, Brugnoli F, Vezzali F, et al
    Protective role of all-trans retinoic acid (ATRA) against hypoxia-induced malignant potential of non-invasive breast tumor derived cells.
    BMC Cancer. 2018;18:1194.
    PubMed     Abstract available

  496. RODRIGUEZ-VELAZQUEZ A, Velez R, Lafontaine JC, Colon-Echevarria CB, et al
    Prevalence of breast and ovarian cancer subtypes in Hispanic populations from Puerto Rico.
    BMC Cancer. 2018;18:1177.
    PubMed     Abstract available

  497. CIFU G, Power MC, Shomstein S, Arem H, et al
    Mindfulness-based interventions and cognitive function among breast cancer survivors: a systematic review.
    BMC Cancer. 2018;18:1163.
    PubMed     Abstract available

  498. HOUVENAEGHEL G, Cohen M, Raro P, De Troyer J, et al
    Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node.
    BMC Cancer. 2018;18:1153.
    PubMed     Abstract available

  499. VAN OMMEN-NIJHOF A, Konings IR, van Zeijl CJJ, Uyl-de Groot CA, et al
    Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    BMC Cancer. 2018;18:1146.
    PubMed     Abstract available

  500. JIN B, Zhang S, Chuang X, Yu P, et al
    Breast cancer and synchronous multiple primary lung adenocarcinomas with heterogeneous mutations: a case report.
    BMC Cancer. 2018;18:1138.
    PubMed     Abstract available

  501. GOTO W, Kashiwagi S, Asano Y, Takada K, et al
    Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer.
    BMC Cancer. 2018;18:1137.
    PubMed     Abstract available

  502. JEONG J, Seo K, Kim ES
    Numerical analysis of intracellular amino acid profiles of breast cancer cells with K-Ras or PI3K mutation in response to kinase inhibitors.
    BMC Cancer. 2018;18:1109.
    PubMed     Abstract available

  503. YE FG, Xia C, Ma D, Lin PY, et al
    Nomogram for predicting preoperative lymph node involvement in patients with invasive micropapillary carcinoma of breast: a SEER population-based study.
    BMC Cancer. 2018;18:1085.
    PubMed     Abstract available

  504. DA COSTA AM, Hashim D, Fregnani JHTG, Weiderpass E, et al
    Overall survival and time trends in breast and cervical cancer incidence and mortality in the Regional Health District (RHD) of Barretos, Sao Paulo, Brazil.
    BMC Cancer. 2018;18:1079.
    PubMed     Abstract available

  505. OBERSTE M, Schaffrath N, Schmidt K, Bloch W, et al
    Protocol for the "Chemobrain in Motion - study" (CIM - study): a randomized placebo-controlled trial of the impact of a high-intensity interval endurance training on cancer related cognitive impairments in women with breast cancer receiving first-line
    BMC Cancer. 2018;18:1071.
    PubMed     Abstract available

  506. RINNERTHALER G, Gampenrieder SP, Petzer A, Burgstaller S, et al
    Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
    BMC Cancer. 2018;18:1074.
    PubMed     Abstract available

  507. VAN DE WIEL HJ, Stuiver MM, May AM, van Grinsven S, et al
    (Cost-)effectiveness of an internet-based physical activity support program (with and without physiotherapy counselling) on physical activity levels of breast and prostate cancer survivors: design of the PABLO trial.
    BMC Cancer. 2018;18:1073.
    PubMed     Abstract available

  508. LEE E, Luo J, Schumacher FR, Van Den Berg D, et al
    Growth factor genes and change in mammographic density after stopping combined hormone therapy in the California Teachers Study.
    BMC Cancer. 2018;18:1072.
    PubMed     Abstract available

    October 2018
  509. GASS P, Lux MP, Rauh C, Hein A, et al
    Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer.
    BMC Cancer. 2018;18:1051.
    PubMed     Abstract available

  510. LUHTALA S, Staff S, Kallioniemi A, Tanner M, et al
    Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
    BMC Cancer. 2018;18:1045.
    PubMed     Abstract available

  511. CHEN L, Qi H, Zhang L, Li H, et al
    Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients.
    BMC Cancer. 2018;18:1038.
    PubMed     Abstract available

  512. ARCINIEGAS CALLE MC, Sandhu NP, Xia H, Cha SS, et al
    Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    BMC Cancer. 2018;18:1037.
    PubMed     Abstract available

  513. JOHNSTON SJ, Ahmad D, Aleskandarany MA, Kurozumi S, et al
    Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair.
    BMC Cancer. 2018;18:1027.
    PubMed     Abstract available

  514. VARGA K, Hollosi A, Paszty K, Hegedus L, et al
    Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells.
    BMC Cancer. 2018;18:1029.
    PubMed     Abstract available

  515. SARINK D, Schock H, Johnson T, Chang-Claude J, et al
    Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.
    BMC Cancer. 2018;18:1010.
    PubMed     Abstract available

  516. SMITH YE, Toomey S, Napoletano S, Kirwan G, et al
    Recombinant PAPP-A resistant insulin-like growth factor binding protein 4 (dBP4) inhibits angiogenesis and metastasis in a murine model of breast cancer.
    BMC Cancer. 2018;18:1016.
    PubMed     Abstract available

  517. DALMASSO B, Hatse S, Brouwers B, Laenen A, et al
    Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy.
    BMC Cancer. 2018;18:1014.
    PubMed     Abstract available

  518. ZHAO Y, Lv F, Chen S, Wang Z, et al
    Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial.
    BMC Cancer. 2018;18:1019.
    PubMed     Abstract available

  519. YANG Y, Cameron J, Bedi C, Humphris G, et al
    Fear of cancer recurrence trajectory during radiation treatment and follow-up into survivorship of patients with breast cancer.
    BMC Cancer. 2018;18:1002.
    PubMed     Abstract available

  520. GEERS J, Wildiers H, Van Calster K, Laenen A, et al
    Oncological safety of autologous breast reconstruction after mastectomy for invasive breast cancer.
    BMC Cancer. 2018;18:994.
    PubMed     Abstract available

  521. REN JT, Wang MX, Su Y, Tang LY, et al
    Decelerated DNA methylation age predicts poor prognosis of breast cancer.
    BMC Cancer. 2018;18:989.
    PubMed     Abstract available

  522. ARAKI K, Ito Y, Fukada I, Kobayashi K, et al
    Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
    BMC Cancer. 2018;18:982.
    PubMed     Abstract available

  523. DA SILVA BB, Eulalio Filho WMN, Costa PVL, Silva RA, et al
    A rare case of primary breast angiosarcoma in a male: a case report.
    BMC Cancer. 2018;18:978.
    PubMed     Abstract available

  524. LI L, Chang B, Jiang X, Fan X, et al
    Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
    BMC Cancer. 2018;18:977.
    PubMed     Abstract available

  525. EUSTACE AJ, Conlon NT, McDermott MSJ, Browne BC, et al
    Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
    BMC Cancer. 2018;18:965.
    PubMed     Abstract available

  526. GHOREISHI Z, Keshavarz S, Asghari Jafarabadi M, Fathifar Z, et al
    Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer.
    BMC Cancer. 2018;18:958.
    PubMed     Abstract available

  527. LEE KH, Kim EY, Yun JS, Park YL, et al
    The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer.
    BMC Cancer. 2018;18:938.
    PubMed     Abstract available

    September 2018
  528. INVERNIZZI M, Corti C, Lopez G, Michelotti A, et al
    Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up.
    BMC Cancer. 2018;18:935.
    PubMed     Abstract available

  529. LOPEZ-PINEDA A, Rodriguez-Moran MF, Alvarez-Aguilar C, Fuentes Valle SM, et al
    Data mining of digitized health records in a resource-constrained setting reveals that timely immunophenotyping is associated with improved breast cancer outcomes.
    BMC Cancer. 2018;18:933.
    PubMed     Abstract available

  530. PELIZZARI G, Arpino G, Biganzoli L, Cinieri S, et al
    An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.
    BMC Cancer. 2018;18:932.
    PubMed     Abstract available

  531. HOYER J, Vasileiou G, Uebe S, Wunderle M, et al
    Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    BMC Cancer. 2018;18:926.
    PubMed     Abstract available

  532. WANG RX, Chen S, Huang L, Shao ZM, et al
    Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.
    BMC Cancer. 2018;18:909.
    PubMed     Abstract available

  533. JOUALI F, Marchoudi N, Talbi S, Bilal B, et al
    Detection of PIK3/AKT pathway in Moroccan population with triple negative breast cancer.
    BMC Cancer. 2018;18:900.
    PubMed     Abstract available

  534. ELWOOD JM, Tawfiq E, TinTin S, Marshall RJ, et al
    Development and validation of a new predictive model for breast cancer survival in New Zealand and comparison to the Nottingham prognostic index.
    BMC Cancer. 2018;18:897.
    PubMed     Abstract available

  535. XIONG Z, Deng G, Wang J, Li X, et al
    Could local surgery improve survival in de novo stage IV breast cancer?
    BMC Cancer. 2018;18:885.
    PubMed     Abstract available

  536. VENTURELLI E, Orenti A, Fabricio ASC, Garrone G, et al
    Correction to: Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.
    BMC Cancer. 2018;18:876.
    PubMed     Abstract available

  537. SCHLIEMANN D, Donnelly M, Dahlui M, Loh SY, et al
    The 'Be Cancer Alert Campaign': protocol to evaluate a mass media campaign to raise awareness about breast and colorectal cancer in Malaysia.
    BMC Cancer. 2018;18:881.
    PubMed     Abstract available

  538. SOBOTA A, Ozakinci G
    Determinants of fertility issues experienced by young women diagnosed with breast or gynaecological cancer - a quantitative, cross-cultural study.
    BMC Cancer. 2018;18:874.
    PubMed     Abstract available

  539. KALINKOVA L, Zmetakova I, Smolkova B, Minarik G, et al
    Decreased methylation in the SNAI2 and ADAM23 genes associated with de-differentiation and haematogenous dissemination in breast cancers.
    BMC Cancer. 2018;18:875.
    PubMed     Abstract available

  540. FAJKA-BOJA R, Marton A, Toth A, Blazso P, et al
    Increased insulin-like growth factor 1 production by polyploid adipose stem cells promotes growth of breast cancer cells.
    BMC Cancer. 2018;18:872.
    PubMed     Abstract available

  541. KIRKHAM AA, Paterson DI, Prado CM, Mackey JM, et al
    Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer.
    BMC Cancer. 2018;18:864.
    PubMed     Abstract available

  542. DUIVON M, Perrier J, Joly F, Licaj I, et al
    Impact of breast cancer on prospective memory functioning assessed by virtual reality and influence of sleep quality and hormonal therapy: PROSOM-K study.
    BMC Cancer. 2018;18:866.
    PubMed     Abstract available

  543. NIAZI MKK, Senaras C, Pennell M, Arole V, et al
    Relationship between the Ki67 index and its area based approximation in breast cancer.
    BMC Cancer. 2018;18:867.
    PubMed     Abstract available

  544. BROEDERS MJM, Allgood P, Duffy SW, Hofvind S, et al
    The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review.
    BMC Cancer. 2018;18:860.
    PubMed     Abstract available

    August 2018
  545. HEIL J, Sinn P, Richter H, Pfob A, et al
    RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial.
    BMC Cancer. 2018;18:851.
    PubMed     Abstract available

  546. HULTSCH S, Kankainen M, Paavolainen L, Kovanen RM, et al
    Association of tamoxifen resistance and lipid reprogramming in breast cancer.
    BMC Cancer. 2018;18:850.
    PubMed     Abstract available

  547. FUMET JD, Wickre M, Jacquot JP, Bizollon MH, et al
    Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer.
    BMC Cancer. 2018;18:839.
    PubMed     Abstract available

  548. FISH EJ, Irizarry KJ, DeInnocentes P, Ellis CJ, et al
    Malignant canine mammary epithelial cells shed exosomes containing differentially expressed microRNA that regulate oncogenic networks.
    BMC Cancer. 2018;18:832.
    PubMed     Abstract available

  549. MENG M, Xue H, Lei J, Wang Q, et al
    A novel approach to monitoring the efficacy of anti-tumor treatments in animal models: combining functional MRI and texture analysis.
    BMC Cancer. 2018;18:833.
    PubMed     Abstract available

  550. VAN BASTELAAR J, Granzier R, van Roozendaal LM, Beets G, et al
    A multi-center, double blind randomized controlled trial evaluating flap fixation after mastectomy using sutures or tissue glue versus conventional closure: protocol for the Seroma reduction After Mastectomy (SAM) trial.
    BMC Cancer. 2018;18:830.
    PubMed     Abstract available

  551. MENG LL, Wang JL, Xu SP, Zu LD, et al
    Low serum gastrin associated with ER(+) breast cancer development via inactivation of CCKBR/ERK/P65 signaling.
    BMC Cancer. 2018;18:824.
    PubMed     Abstract available

  552. RICHTER-EHRENSTEIN C, Maak K, Roger S, Ehrenstein T, et al
    Lesions of "uncertain malignant potential" in the breast (B3) identified with mammography screening.
    BMC Cancer. 2018;18:829.
    PubMed     Abstract available

  553. WANG B, Li D, Rodriguez-Juarez R, Farfus A, et al
    A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
    BMC Cancer. 2018;18:817.
    PubMed     Abstract available

  554. DENARD B, Jiang S, Peng Y, Ye J, et al
    CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy.
    BMC Cancer. 2018;18:813.
    PubMed     Abstract available

  555. AIDERUS A, Black MA, Dunbier AK
    Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers.
    BMC Cancer. 2018;18:805.
    PubMed     Abstract available

  556. AXELSSON U, Ryden L, Johnsson P, Eden P, et al
    A multicenter study investigating the molecular fingerprint of psychological resilience in breast cancer patients: study protocol of the SCAN-B resilience study.
    BMC Cancer. 2018;18:789.
    PubMed     Abstract available

  557. BAEYENS-FERNANDEZ JA, Molina-Portillo E, Pollan M, Rodriguez-Barranco M, et al
    Trends in incidence, mortality and survival in women with breast cancer from 1985 to 2012 in Granada, Spain: a population-based study.
    BMC Cancer. 2018;18:781.
    PubMed     Abstract available

    July 2018
  558. VIALA M, Chiba A, Thezenas S, Delmond L, et al
    Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study.
    BMC Cancer. 2018;18:770.
    PubMed     Abstract available

  559. BEELEN K, Opdam M, Severson T, Koornstra R, et al
    Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.
    BMC Cancer. 2018;18:761.
    PubMed     Abstract available

  560. LEE M, Tayyari F, Pinnaduwage D, Bayani J, et al
    Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival.
    BMC Cancer. 2018;18:750.
    PubMed     Abstract available

  561. GIBBONS JA, Kanwar JR, Kanwar RK
    Correction to: Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer.
    BMC Cancer. 2018;18:749.
    PubMed     Abstract available

  562. RETHORST CD, Hamann HA, Carmody TJ, Sharp KJ, et al
    The Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors.
    BMC Cancer. 2018;18:744.
    PubMed     Abstract available

  563. VASMATZIS G, Wang X, Smadbeck JB, Murphy SJ, et al
    Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2(+) breast cancer samples.
    BMC Cancer. 2018;18:738.
    PubMed     Abstract available

  564. LAMBERT LK, Balneaves LG, Howard AF, Chia SK, et al
    Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
    BMC Cancer. 2018;18:732.
    PubMed     Abstract available

  565. NUSHTAEVA AA, Stepanov GA, Semenov DV, Juravlev ES, et al
    Characterization of primary normal and malignant breast cancer cell and their response to chemotherapy and immunostimulatory agents.
    BMC Cancer. 2018;18:728.
    PubMed     Abstract available

  566. HE Y, Tan EH, Wong ALA, Tan CC, et al
    Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: study protocol of a randomised controlled trial to evaluate the effect of short message service (SMS) reminder.
    BMC Cancer. 2018;18:727.
    PubMed     Abstract available

  567. YOON YN, Choe MH, Jung KY, Hwang SG, et al
    MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells.
    BMC Cancer. 2018;18:716.
    PubMed     Abstract available

  568. SLAOUI M, Zoure AA, Mouh FZ, Bensouda Y, et al
    Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO).
    BMC Cancer. 2018;18:713.
    PubMed     Abstract available

  569. REAL SAS, Parveen F, Rehman AU, Khan MA, et al
    Aberrant Promoter Methylation of YAP Gene and its Subsequent Downregulation in Indian Breast Cancer Patients.
    BMC Cancer. 2018;18:711.
    PubMed     Abstract available

  570. RANGEL N, Fortunati N, Osella-Abate S, Annaratone L, et al
    FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients.
    BMC Cancer. 2018;18:703.
    PubMed     Abstract available

    June 2018
  571. ZOPPINO FCM, Guerrero-Gimenez ME, Castro GN, Ciocca DR, et al
    Comprehensive transcriptomic analysis of heat shock proteins in the molecular subtypes of human breast cancer.
    BMC Cancer. 2018;18:700.
    PubMed     Abstract available

  572. HAYASHIDA T, Jinno H, Mori K, Sato H, et al
    Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
    BMC Cancer. 2018;18:701.
    PubMed     Abstract available

  573. VAN GELDERMALSEN M, Quek LE, Turner N, Freidman N, et al
    Benzylserine inhibits breast cancer cell growth by disrupting intracellular amino acid homeostasis and triggering amino acid response pathways.
    BMC Cancer. 2018;18:689.
    PubMed     Abstract available

  574. EHLERS DK, Fanning J, Salerno EA, Aguinaga S, et al
    Replacing sedentary time with physical activity or sleep: effects on cancer-related cognitive impairment in breast cancer survivors.
    BMC Cancer. 2018;18:685.
    PubMed     Abstract available

  575. GREGOIRE C, Nicolas H, Bragard I, Delevallez F, et al
    Efficacy of a hypnosis-based intervention to improve well-being during cancer: a comparison between prostate and breast cancer patients.
    BMC Cancer. 2018;18:677.
    PubMed     Abstract available

  576. INOUE K, Ninomiya J, Saito T, Kimizuka K, et al
    Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 3
    BMC Cancer. 2018;18:671.
    PubMed     Abstract available

  577. LI Y, Du Y, Sun T, Xue H, et al
    PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.
    BMC Cancer. 2018;18:669.
    PubMed     Abstract available

  578. LI R, Xiao C, Liu H, Huang Y, et al
    Effects of local anesthetics on breast cancer cell viability and migration.
    BMC Cancer. 2018;18:666.
    PubMed     Abstract available

  579. XU H, Xu Y, Ouyang T, Li J, et al
    Low expression of RECQL is associated with poor prognosis in Chinese breast cancer patients.
    BMC Cancer. 2018;18:662.
    PubMed     Abstract available

  580. LOFTEROD T, Mortensen ES, Nalwoga H, Wilsgaard T, et al
    Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes.
    BMC Cancer. 2018;18:654.
    PubMed     Abstract available

  581. VENTURELLI E, Orenti A, Fabricio ASC, Garrone G, et al
    Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.
    BMC Cancer. 2018;18:651.
    PubMed     Abstract available

  582. DUSENGIMANA JMV, Hategekimana V, Borg R, Hedt-Gauthier B, et al
    Pregnancy-associated breast cancer in rural Rwanda: the experience of the Butaro Cancer Center of Excellence.
    BMC Cancer. 2018;18:634.
    PubMed     Abstract available

    May 2018
  583. NATTENMULLER CJ, Kriegsmann M, Sookthai D, Fortner RT, et al
    Obesity as risk factor for subtypes of breast cancer: results from a prospective cohort study.
    BMC Cancer. 2018;18:616.
    PubMed     Abstract available

  584. WHITNEY J, Corredor G, Janowczyk A, Ganesan S, et al
    Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer.
    BMC Cancer. 2018;18:610.
    PubMed     Abstract available

  585. MADHU KRISHNA B, Chaudhary S, Mishra DR, Naik SK, et al
    Estrogen receptor alpha dependent regulation of estrogen related receptor beta and its role in cell cycle in breast cancer.
    BMC Cancer. 2018;18:607.
    PubMed     Abstract available

  586. HOUSE CD, Grajales V, Ozaki M, Jordan E, et al
    IKappaKappaepsilon cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.
    BMC Cancer. 2018;18:595.
    PubMed     Abstract available

  587. MUDDUWA L, Peiris H, Gunasekara S, Abeysiriwardhana D, et al
    KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy.
    BMC Cancer. 2018;18:589.
    PubMed     Abstract available

  588. FORTE L, Turdo F, Ghirelli C, Aiello P, et al
    The PDGFRbeta/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.
    BMC Cancer. 2018;18:586.
    PubMed     Abstract available

  589. BUCZEK E, Denslow A, Mateuszuk L, Proniewski B, et al
    Alterations in NO- and PGI2- dependent function in aorta in the orthotopic murine model of metastatic 4T1 breast cancer: relationship with pulmonary endothelial dysfunction and systemic inflammation.
    BMC Cancer. 2018;18:582.
    PubMed     Abstract available

  590. PARASHAR S, Cheishvili D, Mahmood N, Arakelian A, et al
    DNA methylation signatures of breast cancer in peripheral T-cells.
    BMC Cancer. 2018;18:574.
    PubMed     Abstract available

  591. BATES JP, Derakhshandeh R, Jones L, Webb TJ, et al
    Mechanisms of immune evasion in breast cancer.
    BMC Cancer. 2018;18:556.
    PubMed     Abstract available

  592. BANYS-PALUCHOWSKI M, Fehm T, Janni W, Aktas B, et al
    Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
    BMC Cancer. 2018;18:541.
    PubMed     Abstract available

  593. SHULDINER J, Liu Y, Lofters A
    Incidence of breast and colorectal cancer among immigrants in Ontario, Canada: a retrospective cohort study from 2004-2014.
    BMC Cancer. 2018;18:537.
    PubMed     Abstract available

  594. DOUGAN MM, Li Y, Chu LW, Haile RW, et al
    Metabolomic profiles in breast cancer:a pilot case-control study in the breast cancer family registry.
    BMC Cancer. 2018;18:532.
    PubMed     Abstract available

  595. NAIK A, Al-Yahyaee A, Abdullah N, Sam JE, et al
    Neuropilin-1 promotes the oncogenic Tenascin-C/integrin beta3 pathway and modulates chemoresistance in breast cancer cells.
    BMC Cancer. 2018;18:533.
    PubMed     Abstract available

  596. PENAULT-LLORCA F, Filleron T, Asselain B, Baehner FL, et al
    The 21-gene Recurrence Score(R) assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 tria
    BMC Cancer. 2018;18:526.
    PubMed     Abstract available

  597. LI W, Xu L, Che X, Li H, et al
    C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells.
    BMC Cancer. 2018;18:507.
    PubMed     Abstract available

  598. DI GIROLAMO C, Walters S, Benitez Majano S, Rachet B, et al
    Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with colon, lung or breast cancer in England in 2013.
    BMC Cancer. 2018;18:492.
    PubMed     Abstract available

    April 2018
  599. HUANG S, Murphy L, Xu W
    Genes and functions from breast cancer signatures.
    BMC Cancer. 2018;18:473.
    PubMed     Abstract available

  600. FERNANDO A, Jayarajah U, Prabashani S, Fernando EA, et al
    Incidence trends and patterns of breast cancer in Sri Lanka: an analysis of the national cancer database.
    BMC Cancer. 2018;18:482.
    PubMed     Abstract available

  601. BAUERSFELD SP, Kessler CS, Wischnewsky M, Jaensch A, et al
    The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study.
    BMC Cancer. 2018;18:476.
    PubMed     Abstract available

  602. DOGAN A, Kern P, Schultheis B, Hausler G, et al
    Radiogenic angiosarcoma of the breast: case report and systematic review of the literature.
    BMC Cancer. 2018;18:463.
    PubMed     Abstract available

  603. CATSMAN CJLM, Beek MA, Voogd AC, Mulder PGH, et al
    The COSMAM TRIAL a prospective cohort study of quality of life and cosmetic outcome in patients undergoing breast conserving surgery.
    BMC Cancer. 2018;18:456.
    PubMed     Abstract available

  604. LIUTKAUSKIENE S, Grizas S, Jureniene K, Suipyte J, et al
    Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes.
    BMC Cancer. 2018;18:453.
    PubMed     Abstract available

  605. PODRALSKA M, Ziolkowska-Suchanek I, Zurawek M, Dzikiewicz-Krawczyk A, et al
    Genetic variants in ATM, H2AFX and MRE11 genes and susceptibility to breast cancer in the polish population.
    BMC Cancer. 2018;18:452.
    PubMed     Abstract available

  606. JIN J, Gao Y, Zhang J, Wang L, et al
    Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer.
    BMC Cancer. 2018;18:446.
    PubMed     Abstract available

  607. SEMMLINGER A, von Schoenfeldt V, Wolf V, Meuter A, et al
    EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.
    BMC Cancer. 2018;18:431.
    PubMed     Abstract available

  608. XIAO B, Chen L, Ke Y, Hang J, et al
    Identification of methylation sites and signature genes with prognostic value for luminal breast cancer.
    BMC Cancer. 2018;18:405.
    PubMed     Abstract available

  609. DEFOSSEZ G, Quillet A, Ingrand P
    Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers.
    BMC Cancer. 2018;18:393.
    PubMed     Abstract available

  610. HILLER L, Dunn JA, Loi S, Vallier AL, et al
    Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
    BMC Cancer. 2018;18:391.
    PubMed     Abstract available

  611. VAN DER WAAL D, Verbeek ALM, Broeders MJM
    Breast density and breast cancer-specific survival by detection mode.
    BMC Cancer. 2018;18:386.
    PubMed     Abstract available

  612. BALEKOUZOU A, Yin P, Bekolo CE, Pamatika CM, et al
    Histo-epidemiological profile of breast cancers among women in the Central African Republic: about 174 cases.
    BMC Cancer. 2018;18:387.
    PubMed     Abstract available

  613. PHI XA, Tagliafico A, Houssami N, Greuter MJW, et al
    Digital breast tomosynthesis for breast cancer screening and diagnosis in women with dense breasts - a systematic review and meta-analysis.
    BMC Cancer. 2018;18:380.
    PubMed     Abstract available

  614. HUNG CH, Chen FM, Lin YC, Tsai ML, et al
    Altered monocyte differentiation and macrophage polarization patterns in patients with breast cancer.
    BMC Cancer. 2018;18:366.
    PubMed     Abstract available

  615. LIU Y, Du Y, Hu X, Zhao L, et al
    Up-regulation of ceRNA TINCR by SP1 contributes to tumorigenesis in breast cancer.
    BMC Cancer. 2018;18:367.
    PubMed     Abstract available

    March 2018
  616. AN X, Xu F, Luo R, Zheng Q, et al
    The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.
    BMC Cancer. 2018;18:331.
    PubMed     Abstract available

  617. CHEN J, Zhu Y, Zhang W, Peng X, et al
    Delphinidin induced protective autophagy via mTOR pathway suppression and AMPK pathway activation in HER-2 positive breast cancer cells.
    BMC Cancer. 2018;18:342.
    PubMed     Abstract available

  618. DITTUS KL, Harvey JR, Bunn JY, Kokinda ND, et al
    Impact of a behaviorally-based weight loss intervention on parameters of insulin resistance in breast cancer survivors.
    BMC Cancer. 2018;18:351.
    PubMed     Abstract available

  619. BRONTE G, Rocca A, Ravaioli S, Puccetti M, et al
    Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
    BMC Cancer. 2018;18:348.
    PubMed     Abstract available

  620. XU Y, Yang X, Wang T, Yang L, et al
    Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-gamma-linolenic acid peroxidation dependent mechanism.
    BMC Cancer. 2018;18:330.
    PubMed     Abstract available

  621. SALIMI M, Wang R, Yao X, Li X, et al
    Activated innate lymphoid cell populations accumulate in human tumour tissues.
    BMC Cancer. 2018;18:341.
    PubMed     Abstract available

  622. MARMARA D, Marmara V, Hubbard G
    A national cross-sectional study of adherence to timely mammography use in Malta.
    BMC Cancer. 2018;18:346.
    PubMed     Abstract available

  623. AHN SG, Cha YJ, Bae SJ, Yoon C, et al
    Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer.
    BMC Cancer. 2018;18:320.
    PubMed     Abstract available

  624. WANG YA, Jian JW, Hung CF, Peng HP, et al
    Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
    BMC Cancer. 2018;18:315.
    PubMed     Abstract available

  625. MOODLEY J, Cairncross L, Naiker T, Constant D, et al
    From symptom discovery to treatment - women's pathways to breast cancer care: a cross-sectional study.
    BMC Cancer. 2018;18:312.
    PubMed     Abstract available

  626. ZHANG JJ, Shu H, Hu SS, Yu Y, et al
    Relationship between time elapsed since completion of radiotherapy and quality of life of patients with breast cancer.
    BMC Cancer. 2018;18:305.
    PubMed     Abstract available

  627. MENSAH KB, Oosthuizen F, Bonsu AB
    Cancer awareness among community pharmacist: a systematic review.
    BMC Cancer. 2018;18:299.
    PubMed     Abstract available

  628. MULLER V, Clemens M, Jassem J, Al-Sakaff N, et al
    Long-term trastuzumab (Herceptin(R)) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.
    BMC Cancer. 2018;18:295.
    PubMed     Abstract available

  629. HARDI H, Melki R, Boughaleb Z, El Harroudi T, et al
    Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.
    BMC Cancer. 2018;18:292.
    PubMed     Abstract available

  630. MCANENA PF, McGuire A, Ramli A, Curran C, et al
    Correction to: Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options.
    BMC Cancer. 2018;18:282.
    PubMed     Abstract available

  631. DAVID D, Surendran A, Thulaseedharan JV, Nair AS, et al
    Regulation of CNKSR2 protein stability by the HECT E3 ubiquitin ligase Smurf2, and its role in breast cancer progression.
    BMC Cancer. 2018;18:284.
    PubMed     Abstract available

  632. DIERSSEN-SOTOS T, Palazuelos-Calderon C, Jimenez-Moleon JJ, Aragones N, et al
    Reproductive risk factors in breast cancer and genetic hormonal pathways: a gene-environment interaction in the MCC-Spain project.
    BMC Cancer. 2018;18:280.
    PubMed     Abstract available

  633. SONG Q, Chen Q, Wang Q, Yang L, et al
    ATF-3/miR-590/GOLPH3 signaling pathway regulates proliferation of breast cancer.
    BMC Cancer. 2018;18:255.
    PubMed     Abstract available

  634. NAAB TJ, Gautam A, Ricks-Santi L, Esnakula AK, et al
    MYC amplification in subtypes of breast cancers in African American women.
    BMC Cancer. 2018;18:274.
    PubMed     Abstract available

  635. YANG L, Wang J, Cheng J, Wang Y, et al
    Quality assurance target for community-based breast cancer screening in China: a model simulation.
    BMC Cancer. 2018;18:261.
    PubMed     Abstract available

  636. VONDELING GT, Menezes GL, Dvortsin EP, Jansman FGA, et al
    Burden of early, advanced and metastatic breast cancer in The Netherlands.
    BMC Cancer. 2018;18:262.
    PubMed     Abstract available

  637. ENGEL C, Rhiem K, Hahnen E, Loibl S, et al
    Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
    BMC Cancer. 2018;18:265.
    PubMed     Abstract available

  638. ANWAR SL, Tampubolon G, Van Hemelrijck M, Hutajulu SH, et al
    Determinants of cancer screening awareness and participation among Indonesian women.
    BMC Cancer. 2018;18:208.
    PubMed     Abstract available

  639. SANKATSING VDV, Fracheboud J, de Munck L, Broeders MJM, et al
    Detection and interval cancer rates during the transition from screen-film to digital mammography in population-based screening.
    BMC Cancer. 2018;18:256.
    PubMed     Abstract available

    February 2018
  640. ISFOSS BL, Holmqvist B, Sand E, Forsell J, et al
    Stellate cells and mesenchymal stem cells in benign mammary stroma are associated with risk factors for breast cancer - an observational study.
    BMC Cancer. 2018;18:230.
    PubMed     Abstract available

  641. SOOTICHOTE R, Thuwajit P, Singsuksawat E, Warnnissorn M, et al
    Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.
    BMC Cancer. 2018;18:231.
    PubMed     Abstract available

  642. GAVA F, Rigal L, Mondesert O, Pesce E, et al
    Gap junctions contribute to anchorage-independent clustering of breast cancer cells.
    BMC Cancer. 2018;18:221.
    PubMed     Abstract available

  643. JAASKELAINEN A, Soini Y, Jukkola-Vuorinen A, Auvinen P, et al
    High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer.
    BMC Cancer. 2018;18:223.
    PubMed     Abstract available

  644. BRONSVELD HK, De Bruin ML, Wesseling J, Sanders J, et al
    The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.
    BMC Cancer. 2018;18:224.
    PubMed     Abstract available

  645. HOU MF, Chen PM, Chu PY
    LGR5 overexpression confers poor relapse-free survival in breast cancer patients.
    BMC Cancer. 2018;18:219.
    PubMed     Abstract available

  646. MCANENA PF, Brown JA, Ramli A, Curran C, et al
    Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options.
    BMC Cancer. 2018;18:203.
    PubMed     Abstract available

  647. HUEBNER H, Fasching PA, Gumbrecht W, Jud S, et al
    Filtration based assessment of CTCs and CellSearch(R) based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
    BMC Cancer. 2018;18:204.
    PubMed     Abstract available

  648. WESTVIK AS, Weedon-Fekjaer H, Maehlen J, Liestol K, et al
    Evaluating different breast tumor progression models using screening data.
    BMC Cancer. 2018;18:209.
    PubMed     Abstract available

  649. SIRISENA ND, Adeyemo A, Kuruppu AI, Neththikumara N, et al
    Genetic determinants of sporadic breast cancer in Sri Lankan women.
    BMC Cancer. 2018;18:180.
    PubMed     Abstract available

  650. NOJIMA M, Iwasaki M, Kasuga Y, Yokoyama S, et al
    Correlation between global methylation level of peripheral blood leukocytes and serum C reactive protein level modified by MTHFR polymorphism: a cross-sectional study.
    BMC Cancer. 2018;18:184.
    PubMed     Abstract available

  651. KODAIRA M, Yonemori K, Shimoi T, Yoshida A, et al
    Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.
    BMC Cancer. 2018;18:176.
    PubMed     Abstract available

  652. IBRAHIM M, Yadav S, Ogunleye F, Zakalik D, et al
    Male BRCA mutation carriers: clinical characteristics and cancer spectrum.
    BMC Cancer. 2018;18:179.
    PubMed     Abstract available

  653. KJALLQUIST U, Erlandsson R, Tobin NP, Alkodsi A, et al
    Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs).
    BMC Cancer. 2018;18:174.
    PubMed     Abstract available

  654. AL DOSSARY R, Alkharsah KR, Kussaibi H
    Prevalence of Mouse Mammary Tumor Virus (MMTV)-like sequences in human breast cancer tissues and adjacent normal breast tissues in Saudi Arabia.
    BMC Cancer. 2018;18:170.
    PubMed     Abstract available

  655. LAFOURCADE A, His M, Baglietto L, Boutron-Ruault MC, et al
    Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: the French E3N cohort.
    BMC Cancer. 2018;18:171.
    PubMed     Abstract available

  656. NGUYEN-DUMONT T, Teo ZL, Hammet F, Roberge A, et al
    Is RNASEL:p.Glu265* a modifier of early-onset breast cancer risk for carriers of high-risk mutations?
    BMC Cancer. 2018;18:165.
    PubMed     Abstract available

  657. CORTET M, Bertaut A, Molinie F, Bara S, et al
    Trends in molecular subtypes of breast cancer: description of incidence rates between 2007 and 2012 from three French registries.
    BMC Cancer. 2018;18:161.
    PubMed     Abstract available

  658. LAM WWT, Kwong A, Suen D, Tsang J, et al
    Factors predicting patient satisfaction in women with advanced breast cancer: a prospective study.
    BMC Cancer. 2018;18:162.
    PubMed     Abstract available

  659. LIM JA, Oh CS, Yoon TG, Lee JY, et al
    The effect of propofol and sevoflurane on cancer cell, natural killer cell, and cytotoxic T lymphocyte function in patients undergoing breast cancer surgery: an in vitro analysis.
    BMC Cancer. 2018;18:159.
    PubMed     Abstract available

  660. ABDEL-RAZEQ H, Al-Omari A, Zahran F, Arun B, et al
    Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan.
    BMC Cancer. 2018;18:152.
    PubMed     Abstract available

  661. PENSABENE M, Stanzione B, Cerillo I, Ciancia G, et al
    It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature.
    BMC Cancer. 2018;18:146.
    PubMed     Abstract available

  662. ALUNNI-FABBRONI M, Majunke L, Trapp EK, Tzschaschel M, et al
    Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.
    BMC Cancer. 2018;18:141.
    PubMed     Abstract available

  663. TRAORE BM, El Fakir S, Charaka H, Benaicha N, et al
    Evolution of quality of life in patients with breast cancer during the first year of follow-up in Morocco.
    BMC Cancer. 2018;18:109.
    PubMed     Abstract available

  664. NOVAK J, Besic N, Dzodic R, Gazic B, et al
    Pre-operative and intra-operative detection of axillary lymph node metastases in 108 patients with invasive lobular breast cancer undergoing mastectomy.
    BMC Cancer. 2018;18:137.
    PubMed     Abstract available

  665. BEGUINOT M, Dauplat MM, Kwiatkowski F, Lebouedec G, et al
    Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
    BMC Cancer. 2018;18:129.
    PubMed     Abstract available

  666. KAEWKANGSADAN V, Verma C, Eremin JM, Cowley G, et al
    Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumo
    BMC Cancer. 2018;18:123.
    PubMed     Abstract available

    January 2018
  667. EVANS RL, Pottala JV, Nagata S, Egland KA, et al
    Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality.
    BMC Cancer. 2018;18:119.
    PubMed     Abstract available

  668. HSIEH E, Wang Q, Zhang R, Niu X, et al
    Vertebral fractures among breast cancer survivors in China: a cross-sectional study of prevalence and health services gaps.
    BMC Cancer. 2018;18:104.
    PubMed     Abstract available

  669. FRERES P, Bouznad N, Servais L, Josse C, et al
    Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients.
    BMC Cancer. 2018;18:102.
    PubMed     Abstract available

  670. RICCIARDI GRR, Russo A, Franchina T, Schifano S, et al
    Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
    BMC Cancer. 2018;18:97.
    PubMed     Abstract available

  671. HAQUE I, Ghosh A, Acup S, Banerjee S, et al
    Leptin-induced ER-alpha-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway.
    BMC Cancer. 2018;18:99.
    PubMed     Abstract available

  672. DE LIGT KM, Witteveen A, Siesling S, Steuten LMG, et al
    Shifting breast cancer surveillance from current hospital setting to a community based setting: a cost-effectiveness study.
    BMC Cancer. 2018;18:96.
    PubMed     Abstract available

  673. PARK VY, Kim EK, Kim MJ, Moon HJ, et al
    Breast magnetic resonance imaging for surveillance of women with a personal history of breast cancer: outcomes stratified by interval between definitive surgery and surveillance MR imaging.
    BMC Cancer. 2018;18:91.
    PubMed     Abstract available

  674. PARK JS, Lee ST, Nam EJ, Han JW, et al
    Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
    BMC Cancer. 2018;18:83.
    PubMed     Abstract available

  675. ELWOOD JM, Tin Tin S, Kuper-Hommel M, Lawrenson R, et al
    Obesity and breast cancer outcomes in chemotherapy patients in New Zealand - a population-based cohort study.
    BMC Cancer. 2018;18:76.
    PubMed     Abstract available

  676. BERNAL-ESTEVEZ DA, Garcia O, Sanchez R, Parra-Lopez CA, et al
    Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy.
    BMC Cancer. 2018;18:77.
    PubMed     Abstract available

  677. YU SJ, Yang L, Hong Q, Kuang XY, et al
    MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer.
    BMC Cancer. 2018;18:74.
    PubMed     Abstract available

  678. GARCIA-GUTIERREZ S, Orive M, Sarasqueta C, Legarreta MJ, et al
    Health services research in patients with breast cancer (CAMISS-prospective): study protocol for an observational prospective study.
    BMC Cancer. 2018;18:54.
    PubMed     Abstract available

  679. DALL P, Koch T, Gohler T, Selbach J, et al
    Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study.
    BMC Cancer. 2018;18:51.
    PubMed     Abstract available

  680. TIN TIN S, Elwood JM, Brown C, Sarfati D, et al
    Ethnic disparities in breast cancer survival in New Zealand: which factors contribute?
    BMC Cancer. 2018;18:58.
    PubMed     Abstract available

  681. URRU SAM, Gallus S, Bosetti C, Moi T, et al
    Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
    BMC Cancer. 2018;18:56.
    PubMed     Abstract available

  682. KUMAR D, Haldar S, Gorain M, Kumar S, et al
    Epoxyazadiradione suppresses breast tumor growth through mitochondrial depolarization and caspase-dependent apoptosis by targeting PI3K/Akt pathway.
    BMC Cancer. 2018;18:52.
    PubMed     Abstract available

  683. LOVITT CJ, Shelper TB, Avery VM
    Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins.
    BMC Cancer. 2018;18:41.
    PubMed     Abstract available

  684. PARK E, Yoon J, Choi EK, Kim IR, et al
    A train the trainer program for healthcare professionals tasked with providing psychosocial support to breast cancer survivors.
    BMC Cancer. 2018;18:45.
    PubMed     Abstract available

  685. LOUHICHI T, Saad H, Dhiab MB, Ziadi S, et al
    Stromal CD10 expression in breast cancer correlates with tumor invasion and cancer stem cell phenotype.
    BMC Cancer. 2018;18:49.
    PubMed     Abstract available

  686. HERNANDEZ RK, Wade SW, Reich A, Pirolli M, et al
    Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States.
    BMC Cancer. 2018;18:44.
    PubMed     Abstract available

  687. NZEANGUNG BA, Biwole ME, Kadia BM, Bechem NN, et al
    Evolutionary aspects of non-metastatic breast cancer after primary treatment in a sub-Saharan African setting: a 16-year retrospective review at the Douala general hospital, Cameroon.
    BMC Cancer. 2018;18:32.
    PubMed     Abstract available

  688. NARRANDES S, Huang S, Murphy L, Xu W, et al
    The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
    BMC Cancer. 2018;18:22.
    PubMed     Abstract available

  689. ZHOU K, He X, Huo L, An J, et al
    Development of the body image self-rating questionnaire for breast cancer (BISQ-BC) for Chinese mainland patients.
    BMC Cancer. 2018;18:19.
    PubMed     Abstract available

  690. PATRICIO M, Pereira J, Crisostomo J, Matafome P, et al
    Using Resistin, glucose, age and BMI to predict the presence of breast cancer.
    BMC Cancer. 2018;18:29.
    PubMed     Abstract available

  691. LI M, Li A, Zhou S, Xu Y, et al
    Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    BMC Cancer. 2018;18:4.
    PubMed     Abstract available

    December 2017
  692. LYNGE E, Bak M, von Euler-Chelpin M, Kroman N, et al
    Outcome of breast cancer screening in Denmark.
    BMC Cancer. 2017;17:897.
    PubMed     Abstract available

  693. HUANG LH, Chung HY, Su HM
    Docosahexaenoic acid reduces sterol regulatory element binding protein-1 and fatty acid synthase expression and inhibits cell proliferation by inhibiting pAkt signaling in a human breast cancer MCF-7 cell line.
    BMC Cancer. 2017;17:890.
    PubMed     Abstract available

  694. ASANO Y, Kashiwagi S, Goto W, Takada K, et al
    Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
    BMC Cancer. 2017;17:888.
    PubMed     Abstract available

  695. MERCOGLIANO MF, Inurrigarro G, De Martino M, Venturutti L, et al
    Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
    BMC Cancer. 2017;17:895.
    PubMed     Abstract available

  696. LIU LN, Lin YC, Miaskowski C, Chen SC, et al
    Association between changes in body fat and disease progression after breast cancer surgery is moderated by menopausal status.
    BMC Cancer. 2017;17:863.
    PubMed     Abstract available

  697. KRISHNAN K, Baglietto L, Stone J, McLean C, et al
    Mammographic density and risk of breast cancer by tumor characteristics: a case-control study.
    BMC Cancer. 2017;17:859.
    PubMed     Abstract available

  698. KUMARI K, Keshari S, Sengupta D, Sabat SC, et al
    Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment.
    BMC Cancer. 2017;17:858.
    PubMed     Abstract available

  699. WU Y, Zhang N, Yang Q
    The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast: a meta-analysis.
    BMC Cancer. 2017;17:839.
    PubMed     Abstract available

  700. GAO D, Cazares LH, Fish EN
    CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis.
    BMC Cancer. 2017;17:834.
    PubMed     Abstract available

  701. BAXTER GD, Liu L, Petrich S, Gisselman AS, et al
    Low level laser therapy (Photobiomodulation therapy) for breast cancer-related lymphedema: a systematic review.
    BMC Cancer. 2017;17:833.
    PubMed     Abstract available

  702. PHAM TND, Perez White BE, Zhao H, Mortazavi F, et al
    Protein kinase C alpha enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin.
    BMC Cancer. 2017;17:832.
    PubMed     Abstract available

  703. KO H, Shin J, Lee JE, Nam SJ, et al
    Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women.
    BMC Cancer. 2017;17:821.
    PubMed     Abstract available

  704. OCHNIK AM, Baxter RC
    Insulin-like growth factor receptor and sphingosine kinase are prognostic and therapeutic targets in breast cancer.
    BMC Cancer. 2017;17:820.
    PubMed     Abstract available

  705. HE D, Fang Y, Gunter MJ, Xu D, et al
    Incidence of breast cancer in Chinese women exposed to the 1959-1961 great Chinese famine.
    BMC Cancer. 2017;17:824.
    PubMed     Abstract available

  706. IIZUMI S, Shimoi T, Tsushita N, Bun S, et al
    Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.
    BMC Cancer. 2017;17:819.
    PubMed     Abstract available

  707. THOMAS ET, Del Mar C, Glasziou P, Wright G, et al
    Prevalence of incidental breast cancer and precursor lesions in autopsy studies: a systematic review and meta-analysis.
    BMC Cancer. 2017;17:808.
    PubMed     Abstract available

  708. SENGAL AT, Haj-Mukhtar NS, Elhaj AM, Bedri S, et al
    Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series.
    BMC Cancer. 2017;17:804.
    PubMed     Abstract available

    November 2017
  709. KARTHIK GM, Rantalainen M, Stalhammar G, Lovrot J, et al
    Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling.
    BMC Cancer. 2017;17:802.
    PubMed     Abstract available

  710. QATTAN A, Intabli H, Alkhayal W, Eltabache C, et al
    Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients.
    BMC Cancer. 2017;17:799.
    PubMed     Abstract available

  711. GIORDANO L, Gallo F, Petracci E, Chiorino G, et al
    The ANDROMEDA prospective cohort study: predictive value of combined criteria to tailor breast cancer screening and new opportunities from circulating markers: study protocol.
    BMC Cancer. 2017;17:785.
    PubMed     Abstract available

  712. TAKESHITA T, Yamamoto Y, Yamamoto-Ibusuki M, Sueta A, et al
    Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.
    BMC Cancer. 2017;17:786.
    PubMed     Abstract available

  713. WONG XY, Chong KJ, van Til JA, Wee HL, et al
    A qualitative study on Singaporean women's views towards breast cancer screening and Single Nucleotide Polymorphisms (SNPs) gene testing to guide personalised screening strategies.
    BMC Cancer. 2017;17:776.
    PubMed     Abstract available

  714. SHIROIWA T, Fukuda T, Shimozuma K, Mouri M, et al
    Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.
    BMC Cancer. 2017;17:773.
    PubMed     Abstract available

  715. ISAKOVA J, Talaibekova E, Aldasheva N, Vinnikov D, et al
    The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females.
    BMC Cancer. 2017;17:758.
    PubMed     Abstract available

  716. SAVCI-HEIJINK CD, Halfwerk H, Koster J, Van de Vijver MJ, et al
    Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer.
    BMC Cancer. 2017;17:755.
    PubMed     Abstract available

  717. LI J, Lai Y, Ma J, Liu Y, et al
    miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    BMC Cancer. 2017;17:745.
    PubMed     Abstract available

  718. KHAN UT, Walker AJ, Baig S, Card TR, et al
    Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis.
    BMC Cancer. 2017;17:747.
    PubMed     Abstract available

  719. ERNST J, Mehnert A, Dietz A, Hornemann B, et al
    Perceived stigmatization and its impact on quality of life - results from a large register-based study including breast, colon, prostate and lung cancer patients.
    BMC Cancer. 2017;17:741.
    PubMed     Abstract available

  720. MINICHILLO S, Gallelli I, Barbieri E, Cubelli M, et al
    Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report.
    BMC Cancer. 2017;17:722.
    PubMed     Abstract available

  721. QUINTERO M, Adamoski D, Reis LMD, Ascencao CFR, et al
    Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
    BMC Cancer. 2017;17:727.
    PubMed     Abstract available

  722. GOHR K, Hamacher A, Engelke LH, Kassack MU, et al
    Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    BMC Cancer. 2017;17:711.
    PubMed     Abstract available

  723. LANZ HL, Saleh A, Kramer B, Cairns J, et al
    Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform.
    BMC Cancer. 2017;17:709.
    PubMed     Abstract available

    October 2017
  724. REPO H, Gurvits N, Loyttyniemi E, Nykanen M, et al
    PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival.
    BMC Cancer. 2017;17:705.
    PubMed     Abstract available

  725. D'ALOISIO AA, Nichols HB, Hodgson ME, Deming-Halverson SL, et al
    Validity of self-reported breast cancer characteristics in a nationwide cohort of women with a family history of breast cancer.
    BMC Cancer. 2017;17:692.
    PubMed     Abstract available

  726. KIM HM, Lee J, Koo JS
    Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
    BMC Cancer. 2017;17:690.
    PubMed     Abstract available

  727. JAHN B, Rochau U, Kurzthaler C, Hubalek M, et al
    Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.
    BMC Cancer. 2017;17:685.
    PubMed     Abstract available

  728. LYSZCZARZ B, Nojszewska E
    Productivity losses and public finance burden attributable to breast cancer in Poland, 2010-2014.
    BMC Cancer. 2017;17:676.
    PubMed     Abstract available

    September 2017
  729. ABHYANKAR N, Hoskins KF, Abern MR, Calip GS, et al
    Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer - a SEER analysis.
    BMC Cancer. 2017;17:659.
    PubMed     Abstract available

  730. REITHMEIER A, Panizza E, Krumpel M, Orre LM, et al
    Tartrate-resistant acid phosphatase (TRAP/ACP5) promotes metastasis-related properties via TGFbeta2/TbetaR and CD44 in MDA-MB-231 breast cancer cells.
    BMC Cancer. 2017;17:650.
    PubMed     Abstract available

  731. REYNOLDS KL, Bedard PL, Lee SH, Lin CC, et al
    A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
    BMC Cancer. 2017;17:646.
    PubMed     Abstract available

  732. HUSSAIN AR, Siraj AK, Ahmed M, Bu R, et al
    XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis.
    BMC Cancer. 2017;17:640.
    PubMed     Abstract available

  733. DEB S, Gorringe KL, Pang JB, Byrne DJ, et al
    BRCA2 carriers with male breast cancer show elevated tumour methylation.
    BMC Cancer. 2017;17:641.
    PubMed     Abstract available

    May 2017
  734. VOELS B, Wang L, Sens DA, Garrett SH, et al
    The unique C- and N-terminal sequences of Metallothionein isoform 3 mediate growth inhibition and Vectorial active transport in MCF-7 cells.
    BMC Cancer. 2017;17:369.
    PubMed     Abstract available

  735. DEMOOR-GOLDSCHMIDT C, Drui D, Doutriaux I, Michel G, et al
    A French national breast and thyroid cancer screening programme for survivors of childhood, adolescent and young adult (CAYA) cancers - DeNaCaPST programme.
    BMC Cancer. 2017;17:326.
    PubMed     Abstract available

  736. BOGAN D, Meile L, El Bastawisy A, Yousef HF, et al
    The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    BMC Cancer. 2017;17:329.
    PubMed     Abstract available

  737. CHIN-QUEE K, Donahue HJ
    MDA-MET-conditioned-medium augments the chemoattractant-dependent migration of MDA-MET cells towards hFOB-conditioned medium and increases collagenase activity.
    BMC Cancer. 2017;17:324.
    PubMed     Abstract available

    April 2017
  738. JUNG SY, Sobel EM, Papp JC, Zhang ZF, et al
    Effect of genetic variants and traits related to glucose metabolism and their interaction with obesity on breast and colorectal cancer risk among postmenopausal women.
    BMC Cancer. 2017;17:290.
    PubMed     Abstract available

    March 2017
  739. BERNTSEN S, Aaronson NK, Buffart L, Borjeson S, et al
    Design of a randomized controlled trial of physical training and cancer (Phys-Can) - the impact of exercise intensity on cancer related fatigue, quality of life and disease outcome.
    BMC Cancer. 2017;17:218.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.